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Polycystic ovary syndrome (PCOS) is reported to be the most common endocrine 
disorder affecting women of reproductive age. According to the National Institutes of 
Health, the prevalence of PCOS is estimated to be 8–12%, but some recent screenings 
suggest even larger numbers [1]. 
In addition to androgen excess (AE), oligomenorrhea, infertility, and insulin 
resistance (IR), PCOS is frequently accompanied by a higher prevalence of metabolic 
disorders and cardiovascular risk factors. Different PCOS phenotypes differ 
significantly in their cardiometabolic risk profile depending on the presence and 
severity of AE. Although PCOS diagnosis and care have improved significantly during 
the last three decades, longer-time-scale data regarding cardiovascular morbidity, 
mortality, and the possible beneficial effects of different interventions are still missing. 
Although the pathophysiology of PCOS is not fully understood, possible 
connections between cardiometabolic complications, IR, genetic polymorphisms, and 
environmental factors have been identified recently. According to some estimations, 
30–40% of the world’s population is reported to have IR, and the proportion is even 
greater (75%) among PCOS women [2]. Normally, female gender has a positive impact 
on IR, body fat composition, and cardiometabolic risk. This is supported by the fact that 
estrogen replacement after menopause has beneficial effects on insulin sensitivity and 
keeps cardiovascular risk low [3]. A higher-than-normal serum concentration of sexual 
steroids of the opposite gender increases the prevalence of coronary disease, stroke, and 
hypertension, as proven by data from individuals that underwent female-to-male sex-
change interventions [4]. 
Vitamin D deficiency (VDD) affects approximately 30–50% of the world’s 





supplements, which are widely accepted in the United States) could help achieve 
sufficient vitamin D (VD) serum levels. Recently, an inverse relationship was found 
between VD serum levels and the occurrence of coronary heart disease. Previous studies 
reported that hyperinsulinemia, VDD, and AE coexist in PCOS women [5, 6], and the 
prevalence of VDD in women with AE is predicted to be 67–85% worldwide.  
 




The first description of PCOS dates back to 1721, when Vallisneri described a 
young, moderately obese, and infertile woman with “two larger than normal ovaries, 
bumpy, shiny, just like pigeon eggs” [7]. In 1935, Stein and Leventhal presented the 
cases of seven fertile reproductive-aged women with similar endocrine conditions and 
ovarian morphology. They identified infertility, amenorrhea, hirsutism, enlarged ovaries 
with multiple cysts, and thickened ovarian tunica as leading symptoms and proposed 
PCOS as a name for this condition. They also began to perform wedge biopsies on their 
patients, which was demonstrated to be an effective treatment; later on, 90% reported 
normal menstruation cycles and 65% became pregnant [8]. 
During the last two decades, the definition of PCOS has changed and improved. 
The first commonly used diagnostic criteria were proposed in 1990 by the National 
Institutes of Health. This definition regarded oligo-anovulation and any signs of AE 
(either biochemical or clinical) as sufficient for diagnosis only if other endocrine 
disorders had already been excluded as the underlying cause. In 2003, the European 
Society of Human Reproduction and Embryology and the American Society of 
Reproductive Medicine organized a consensus workshop to refine and reconsider the 
definition of PCOS. The results were summarized in the Rotterdam criteria, which 
introduced ultrasound diagnosis of polycystic ovaries as a new provision. It also 





Although oligo-anovulation remained a lead criterion, two of the three above-mentioned 
conditions were sufficient for diagnosis [9]. 
As the Rotterdam criteria broadened the spectrum of patients and focused more on 
women with AE, it was widely criticized. Therefore, in 2006, the Androgen Excess 
PCOS Society discussed the topic again and proposed the currently accepted definition. 
Today, an excess of androgen activity, oligo-anovulation and/or polycystic ovaries, and 
exclusion of other diseases or conditions that could cause an excess of androgen activity 
are necessary to diagnose PCOS [10]. Based on these criteria, four different phenotypes 
of PCOS have been described [11, 12]: 
 The hyperandrogenic form with oligo-anovulation and polycystic ovarian 
morphology, which is the “classic” PCOS phenotype. 
 The hyperandrogenic form with oligo-anovulation without relevant signs of 
polycystic ovarian morphology. 
 Hyperandrogenism with polycystic ovarian morphology but no relevant 
ovulation disturbances. 




Signs of AE should be judged based upon the presence of hirsutism and elevated 
levels of circulating androgens, mainly testosterone (T) and its active metabolite, 5-
dihidrotestosterone (DHT). In cases of hirsutism, excessive terminal (coarse) hair is 
found in a male pattern. This differs from hypertrichosis, in which there is no typical 
pattern and excessive growth of hair follicles all over the body. High levels of 
circulating androgen enhance cytokine and specific growth factor production and trigger 
the conversion of T to DHT by 5α-reductase in the pilosebaceous unit, leading less 
visible vellus hair to turn into terminal hair [12]. The modified Ferriman-Gallwey scale 
is used for clinical evaluation [13]. In addition, hirsutism shows racial differences; 
Caucasian or African women develop it much more frequently than East Asian women 





Analysis of circulating androgen levels requires sensitive methods, such as liquid 
chromatography and tandem mass spectrometry, immunochemiluminescence, or 
radioimmunoassay [16]. One standard method is to use high-quality T and steroid-
binding globulin (SHBG) assays, which provide the total T and calculated free T. 
Ideally, these tests should be performed in the follicular phase, and reference hormone 
values should be obtained from women with regular menses [17, 18]. Another candidate 
hormone for AE measurement is dehydroepiandrosterone, which well represents adrenal 
hyperandrogenism. Although dehydroepiandrosterone itself is a weak androgen, it 
serves as a substrate for further androgen synthesis. The serum level of its precursor, 
dehydroepiandrosterone sulphate (DHEAS), is higher in PCOS women and is associated 
with elevated prevalence of IR [19]. According to some recent data, 75% of the adult 
PCOS female population has increased levels of all three biomarkers (T, 
androstenedione, and DHEAS), but serum T levels are the most frequently tested 
overall [20]. 
Anti-Müllerian hormone (AMH) is not an androgen, but a member of the 
transforming growth factor-β superfamily, which recently became of interest in relation 
to PCOS. Preantral or small antral follicle release of AMH clearly correlates with their 
number as well as the secretory activity of granulosa cells. Above all, AMH acts in 
opposition to follicle-stimulating hormone (FSH) in the ovarian tissue and shifts steroid 
synthesis towards androgenesis [21, 22]. Neurons that secrete gonadotropin-releasing 
hormone (GnRH) dispose AMH receptors on their surface. If the serum level of AMH is 
high, both GnRH neuronal firing and the pulsatility of gonadotropin secretion are more 
intense, which increases the secretion of luteinizing hormone (LH) and results in AE 
[23]. Although the level of AMH is relatively stable during the menstrual cycle, it is 
limited as a biomarker of PCOS. AMH secretion is age-dependent, reaching its peak in 
the individual’s early 20s and declining slowly until menopause [24]. In this context, 
age-specific normal values of AMH levels are probably needed. 
Oligomenorrhea is present in 85% of the whole PCOS population [10]. It is not 
always easy to determine the right diagnosis; on one hand, chronic anovulation could 
occur among normal fertile females, but on the other hand, some PCOS women could 
have normal ovulatory patterns. According to the criteria, oligo-anovulation leads 





[25]. Low serum progesterone levels (lower than 3–4 ng/ml) from the midluteal phase 
of the cycle could help to prove the diagnosis [26]. 
Previously, polycystic ovarian morphology was defined after ultrasound 
examination based upon the presence of 10 or more follicles measuring 2–8 mm in 
diameter. Typically, follicles are arranged around the dense core of the stroma or are 
randomly scattered in the enlarged stroma [27]. Later on, this definition was changed 
due to modifications made by the Rotterdam criteria. The current definition requires the 
presence of 12 or more follicles measuring 2–9 mm in diameter in each ovary and/or 
increased ovarian volume (>10 ml) in at least one ovary. Furthermore, smaller follicle 
size (diameter of 2–5 mm) correlates strongly with serum T, DHT, and DHEAS levels 
and the severity of IR [28]. As PCOS may alter ovarian aging, some studies indicate the 
importance of adolescent ultrasound examinations. Early enlargement of the ovaries 
could be detected right after menarche, which provides the opportunity to implement 
early goal-oriented therapy [29]. Multiple follicles can often be detected at this age, 
whilst total ovarian volume correlates better with PCOS prevalence in adulthood. Other 
studies focusing on the number of follicles suggested raising the threshold from 12 to 25 
and argued that PCOS morphology is commonly found in normal women without AE 
and oligo-anovulation [30]. 
 
1.2.3 Pathophysiology of PCOS 
 
The underlying pathomechanism of PCOS is still under debate. Androgen 
overproduction, which is due to disturbed gonadotropin, FSH, and LH secretion, is the 
cornerstone of PCOS. Under normal circumstances, female androgen production takes 
place in the adrenal glands and the ovaries. Figures 1A and 1B show the different steps 
of adrenal and ovarian sex hormone genesis. Circulating levels of androgens could be 
the result of direct secretion or enzymatic conversion of 17-ketosteroids into 
androstenedione, mainly in the liver, skin, and adipose tissue. In the adrenal glands, 
androgen production is regulated by autocrine and paracrine signaling, whilst the 








Figure 1 Different steps of adrenal and ovarian sex hormone genesis. A. Adrenal 
steroid hormone genesis in a human. Different types of steroid hormones are labelled 
with different colors. The first step is the conversion of cholesterol into pregnenolone, 
which is catalyzed by the 17α-hydroxylase/17,20-lyase enzyme. Androstenedione is the 
substrate of 17β-hydroxysteroid dehydrogenase and aromatase that leads to the 
formation of T and estrone. This figure is taken from the article 







report” [31]. B. Sexual steroid hormone biosynthesis in an ovary. In the ovarian theca 
cells, androgen formation is stimulated by LH and modulated by cytochrome P450c17, 
which engages in both 17-hydroxylase and 17,20-lyase activities. The formed 
androstenedione is taken up by granulosa cells and helps the formation of estrogens. 
Androstenedione in theca cells is converted to T, which leads to hyperandrogenism. 
Insulin enhances androgen synthesis in the theca cells. This figure is taken from the 
article “Association of polycystic ovary syndrome with metabolic syndrome and 
gestational diabetes: Aggravated complication of pregnancy” [32]. HSD, 
hydroxysteroid dehydrogenase; LH, luteinizing hormone. 
 
 
In PCOS, ovarian androgen synthesis is the main cause of AE, but adrenal 
androgen production is reported to be elevated in 30–50% of PCOS women. 
Additionally, these women show enhanced 17-ketosteroid responses to 
adrenocorticotropic hormone [7, 12]. 
Androgens play a key role in the early gonadotropin independent phase of the 
menstrual cycle by initiating the growth of primordial follicles and recruiting small 
preantral follicles. A similar mechanism can be observed in girls during premenarche, 
when adrenal androgen synthesis helps induce gonadarche and menarche. Moreover, 
girls with “hyperpuberty” are at higher risk for subsequent development of PCOS [33, 
34]. 
During the normal follicular phase of the menstrual cycle, LH triggers the 
androgenic precursor output of the ovarian theca cells and FSH regulates their 
conversion into estrogens (estradiol) at the granulosa cells. This hormonal balance 
promotes normal folliculogenesis in fertile females. 
The main feature of PCOS is follicular arrest, which is provoked by an imbalance 
of LH, FSH, and sexual steroids. Increased follicular activation, a higher proportion of 
primordial follicles, and a corresponding increase in activated growing (primary) 
follicles are also typical features. Activated follicles show a lower rate of atresia and fail 
to mature. These characteristics of PCOS could be explained by the observed high 





consequence, theca cell hyperplasia occurs as well. At the level of the hypothalamic–
pituitary axis, gonadotropin release increases and GnRH pulse secretion occurs at a 
rapid frequency, which keeps LH levels high [35]. 
In 1993, Crawley summarized possible theories for the development of AE [7, 
36]: 
 The top-down theory claims that the hypothalamic–pituitary axis is 
responsible for AE due to central dysregulation of GnRH firing, which 
leads to LH overproduction. The end effect is follicular theca cell 
hyperplasia and aromatase upon activation. In rats and mice, imbalance of 
GnRH secretion resulted in changes at the level of LH and FSH synthesis 
[37]. 
 The bottom-up hypothesis presumes the failure of adrenal sexual steroid 
synthesis. In this case, failure of peripheral androstenedione conversion is 
responsible for pituitary LH overproduction and, thus, increased ovarian 
androgen synthesis [36]. 
 The androgen theory summarizes different explanations for the first 
occurrence of AE. According to the theory, upon sudden peripheral 
(ovarian, adrenal) androgen overproduction or exposure, PCOS is induced. 
The so-called “fetal AE” theory supports the notion of early encounter 
with high serum androgen levels that provoke the onset of PCOS in 
adulthood. This explanation is also supported by some non-primate models 
that successfully produced phenotypical changes close to those seen in 
humans affected by PCOS [38]. Other explanations focus on the 
dysfunction of specific enzymes, like 11β-hydroxysteroid dehydrogenase. 
It has two subtypes (type 1 and 2) that coordinate to inactivate and 
reactivate adrenal glucocorticoid. Activation of subtype 2 triggers 11β-
hydroxy androstenedione, 11β-hydroxytestosterone, and 11β-
hydroxyprogesterone production [39]. Dysfunction of cytochrome 
P450c17a also leads to disturbed androgen synthesis, as it is responsible 
for both 17α-hydroxylase and 17-20-desmolase activities in the ovarian 
and adrenal cells. As a single gene encodes this cytochrome P450 enzyme, 





 The insulin theory proposes IR as a provoking factor for AE. The major 
actions of insulin are mediated via three different pathways. Its metabolic 
effects are regulated by the phosphatidyl-inositol 3-kinase (PI3-K) 
pathway, whilst the mitogenic effects of insulin are coordinated by 
mitogen-activated protein kinases (MAPKs). The protein kinase C 
pathway is responsible for phospholipase C activation, which enhances 
second messengers in several tissues. In ovarian theca cells, LH increases 
steroidogenesis via the cyclic adenosine monophosphate–protein kinase A 
pathway. Insulin could trigger the accumulation of cyclic adenosine 
monophosphate through the PI3-K and protein kinase C cascade and 
increases LH secretion, which could prove the existence of cross-talk 
between LH and insulin signaling in ovarian tissue [41]. 







Figure 2. Endocrine disturbances in the background of PCOS. Decreased sensitivity 
of the GnRH pulse generator and increased GnRH firing frequency provoke LH hyper- 
and FSH hyposecretion and therefore lead to hyperandrogenism and ovarian arrest. 
Moreover, hyperinsulinemia results in further LH production and increases the level of 
circulating androgens by inhibiting the production of SHBG. Abbreviations: GnRH, 
gonadotropin-releasing hormone; LH, luteinizing hormone, FSH, follicle-stimulating 
hormone; SHBG, sex hormone-binding globulin; IGF-1, insulin-like growth factor 1; 
IGFBP-1, insulin-like growth factor 1 binding protein; P450c17alpha, 17-alpha 
hydroxylase. This figure is adopted from the article “Polycystic ovary syndrome and 





1.3 Etiology of PCOS 
 
Although the Rotterdam criteria suggest that PCOS is a well-characterized 
endocrine disorder, its symptoms are in fact highly variable and heterogeneous. 
Genetics, environmental background, nutrition, and ethnicity are important factors 
affecting its development. PCOS has the same prevalence among Caucasian women 
from the United States, Spain, and Australia (6–9%), but Southeastern Asian women—
especially Chinese women (2.2%) have the lowest prevalence in the world [1]. The 
Hispanic PCOS population in the United States shows higher rates of hirsutism, 
metabolic syndrome (MetS), and obesity compared to Caucasians [43].  
Lifestyle factors and eating habits also play an important role in the development 
of PCOS. The Western diet contains many processed foods, which are rich in advanced 
glycation end products. These glycotoxins enhance intracellular signal transduction, 
trigger pro-inflammatory gene transcription, macrophage activation, cytokine (e.g., 
interleukins 1, 6, and 8), chemokine release, and reactive oxygen species production 
(i.e., the Maillard reaction) [44, 45]. Additionally, the circulating level of glycotoxins is 
well correlated with central obesity, waist-to-hip ratio, and IR in PCOS women [44, 46]. 
Obesity is a common health problem that affects 50–80% of patients [47], 
strongly influencing their reproductive function and cardiometabolic health [43]. 
Approximately 75–80% of PCOS women suffer from IR, a significantly higher 
proportion than in the age- and body mass index-matched female population [48]. Non-
alcoholic fatty liver disease is believed to be one of the major consequences of IR, and it 
shows a clear correlation with AE. Its estimated prevalence may exceed 40% among 
obese PCOS women [49]. 
PCOS is associated with a significant increase in risk factors such as 
cardiovascular disease, atherosclerosis, obesity, MetS, dyslipidemia, type 2 diabetes 
mellitus (T2D), and IR [12, 50]. Cognitive or mood disorders, like depression and 
anxiety, are more frequent among PCOS women compared to the healthy female 





Figure 3 shows the complex etiology of PCOS.  
 
Figure 3. Complex etiology of PCOS. Genetics, epigenetics, and lifestyle could 
promote the development of hyperandrogenism, obesity, IR, and chronic inflammation. 
Hyperandrogenism and IR are responsible for further clinical, metabolic, reproductive 
and psychosocial consequences of these endocrine disturbances. Abbreviations: IGT, 
impaired glucose tolerance; T2D, type 2 diabetes mellitus; CV risk factors, 
cardiovascular risk factors. This figure is adopted from the article “The genetics of 
polycystic ovary syndrome: An overview of candidate gene systematic reviews and 
genome-wide association studies” [52]. 
 
 
1.3.1 Metabolic syndrome 
 
The key elements of MetS are AE and IR, which join together all the necessary 





Organization, MetS is characterized by hyperglycemia (fasting glucose levels of 
5.6 mmol/L or above), central obesity (increased waist circumference according to 
population- and country-specific definitions), elevated arterial blood pressure 
(130/85 mmHg or above), high total triglyceride (1.7 mmol/L or above), and a low high-
density lipoprotein cholesterol (HDL-C) level (less than 1.29 mmol/L in women) [53, 
54]. 
The prevalence of MetS is two to four times higher in the PCOS population than 
among healthy individuals. The presence of central obesity has a high impact on MetS 
prevalence [53]. If central obesity is combined with AE, the prevalence reaches 
approximately 29%, and if it is combined with polycystic morphology and AE, it 
reaches 35% [55]. The prevalence of IR is also around 30% in PCOS females, and it 
increases to 45–50% if centripetal obesity is present. 
Higher triglyceride, lower HDL-C, and higher low-density lipoprotein cholesterol 
(LDL-C) levels are more common in PCOS patients than in the non-PCOS population 
[56]. Recently, some new biomarkers have been introduced to improve evaluation. For 
example, lipoprotein is a predictor of early-onset cardiovascular disease in PCOS 
women, even if they have normal lipid profiles [57]. In addition, reduced efflux capacity 
from macrophages, an indicator of HDL-C function, was decreased in the PCOS 
population [58].  
Several rodent and non-primate models support the notion that fetal or adolescent 
exposure to androgens (mainly T or DHT) could provoke MetS [59, 60]. Furthermore, 
in a mouse model of letrozole-induced PCOS, antiandrogen therapy ameliorated 
symptoms of MetS and reduced body weight and adipocyte size [61]. Enlargement of 
adipocytes (hypertrophic obesity) is typical in PCOS patients. Apparently, this 
hypertrophy is due to disturbed lipolysis, reduced lipoprotein lipase activity, and altered 
storage capacity of adipocytes [62]. 
The most promising results for MetS were achieved if both AE and IR were 
treated at the same time. Flutamide is an androgen receptor antagonist that, together 
with metformin, has been reported to reduce plasma androgen indices and improve 





while combination with flutamide decreased intestinal androgen receptor expression and 
increased estrogen receptor α expression. Hepatic and intestinal insulin and insulin 
receptor signaling were also improved by this “double” therapy [63].  
Fasting blood sugar levels and dyslipidemia (characterized by a high triglyceride 
level and low HDL-C ratio) were found to be the strongest indicators of MetS onset. A 
study conducted in India reported that dyslipidemia was present in 90% of adolescent 
PCOS girls. Interestingly, more than 20% of these girls had already developed glucose 
intolerance, which indicates early onset of dysfunctional glucose metabolism and 
insulin sensitivity [64]. Insulin sensitivity and circulating SHBG levels also show a 
strong correlation, as IR is often associated with reduced SHBG levels and elevation of 
free androgens. 
The development of MetS could be associated with failure of central regulation 
and energy metabolism. The role of decreased sympathetic tone has already been 
described in rodent models of neonatal androgenization, leptin resistance, and DHT-
induced female AE. Central hyperleptinemia with peripheral leptin resistance 
(unresponsiveness to its anorexigenic effects) is often detected in MetS cases. In 
addition, energy intake is regulated by the firing activity of specialized fuel-sensing 
neurons of the hypothalamus. The hypothalamic expression of proopiomelanocortin 
neurons is found to be diminished in hyperandrogenic female mice. Moreover, chronic 
AE increases the adrenocorticotropic hormone sensitivity of proopiomelanocortin cell 
bodies and decreases fiber projection intensity, leading to increased energy intake and 
obesity. Reduced levels of α-melanocyte-stimulating hormone are also detected in AE 
cases [65]. 
 
1.3.2 Insulin resistance 
 
1.3.2.1 Definition and diagnosis 
Under normal circumstances, insulin regulates glucose homeostasis by enhancing 





muscle cells), decreasing hepatic glucose production, and modulating free fatty acid 
(FFA) release by lipolysis. The classic definition of IR is characterized by damage of all 
three pathways, which results in impaired glucose intake and metabolism with a 
compensatory increase in beta-cell insulin production and hyperinsulinemia. In the long 
term, hyperglycemia and hyperinsulinemia promote chronic inflammation and oxidative 
stress, which contribute to the development of arterial hypertension, dyslipidemia, 
visceral adiposity, endothelial dysfunction, a prothrombotic state, and T2D. 
Among patients diagnosed with PCOS based on the Rotterdam criteria, 70% have 
impaired glucose tolerance or T2D, which are mainly diagnosed in their fourth decade 
of their life. Some recent data show that the prevalence of IR is almost the same among 
adolescents and young adults suffering from PCOS [64, 66], which suggests early onset 
of dysfunctional insulin signaling. Patients with AE and obesity are at the highest risk, 
although the lean PCOS phenotype seems to play no protective role in the development 
of dysglycemia. Elevated basal insulin secretion with insufficient insulin secretory 
responses to a glucose load are the main characteristics of IR in PCOS patients. 
Furthermore, in most cases, IR is selective and affects the metabolic—but not the 
mitogenic—signaling pathways [53, 67]. 
The hyperinsulinemic–euglycemic glucose clamp technique is the gold-standard 
method to assess metabolic IR in vivo. The clamp technique enables quantitative 
evaluation of the effect of insulin on whole-body glucose uptake, while euglycemia is 
maintained with the administration of different insulin concentrations and adjusted 
amounts of glucose infusion [68]. Insulin-mediated glucose disposal is used as an 
indicator of insulin sensitivity. It could be defined under steady-state conditions in 
which the amount of infused glucose equals the amount of glucose taken up by the 
peripheral tissues. Hepatic glucose production and renal elimination can be measured 
with the help of isotopic-labelled glucose infusion through the clamp [66]. 
Sequential multiple insulin dose euglycemic clamps provide the opportunity to 
investigate the concentration-dependent saturable actions of insulin in vivo. On one 
hand, any type of alteration in insulin receptor binding or phosphorylation could be 
assessed by insulin sensitivity, which is evaluated based on the concentration required 





insulin is defined by insulin responsiveness, which reflects post-receptor events such as 
glucose transporter translocation. Interestingly, there is no glucose load or dose-
dependent difference in insulin sensitivity values between lean and obese PCOS 
women. This finding suggests that both phenotypes act similarly to compensate for 
sudden glucose uptake. In addition, basal endogenous glucose production and half-
maximal insulin response are disturbed only in obese PCOS women, which may support 
the notion of a possible connection point between impaired lipid metabolism and IR 
[69]. 
The clamp technique could be used to measure insulin clearance, which is 
strongly related to insulin receptor activation. In hyperinsulinemia cases, longer 
elimination time and clearance of insulin should be expected. Interestingly, there is no 
significant difference between hyperinsulinemic PCOS patients and healthy individuals 
in terms of posthepatic insulin clearance. Nevertheless, the C-peptide ratio was elevated 
in PCOS patients, which suggests hepatic dysregulation of insulin extraction [70]. 
Another method for measuring whole-body insulin sensitivity in subjects without 
diabetes is the frequently sampled intravenous glucose tolerance test with minimal 
model analysis. The minimal model allows for evaluation of insulin sensitivity (i.e., the 
sensitivity index), which correlates well with glucose-uptake-stimulated insulin action 
and suppressed glucose production [71]. 
Although these techniques offer correct and complex results regarding whole-
body insulin sensitivity, the oral glucose tolerance test (OGTT) and fasting glucose and 
insulin level measurements are still the most commonly used clinical techniques. OGTT 
values correlate well with the results for the euglycemic glucose clamp and frequently 
sampled intravenous glucose tolerance test, but they are insensitive to large changes in 
insulin sensitivity and inaccurate for evaluation of β-cell dysfunction [66]. 
 
1.3.2.2 Metabolic effects of insulin resistance in PCOS 
The metabolic effects of IR are mainly detected in skeletal muscle and adipose 





which exceeds 70–85% of the whole-body glucose uptake under normal circumstances. 
If this capacity reaches its maximum, de novo lipogenesis takes place in the liver, which 
leads to an increased level of circulating FFAs. In the adipose tissue, failure of insulin 
signaling could provoke lipolysis, which also serves as a source of FFAs. Consequently, 
chronic inflammation and ectopic fat deposition occur, leading to vascular and 
metabolic complications. 
In skeletal muscle, insulin receptor activation is followed by transmembrane 
translocation of glucose transporter 4 to promote glucose uptake. Recent studies found 
that reduced transcription of the β subunit can be detected in PCOS skeletal muscle 
cells. Although this mechanism provokes IR, it has some protective effects as well. If 
hyperinsulinemia persists, lower expression of the insulin receptor subunit would help 
to maintain the euglycemic state [72]. Additionally, glucose transporter 4 translocation 
problems could be associated with insulin downstream signaling failure. Some in vitro 
studies conducted with PCOS myotubes revealed that insulin receptor substrate 2-
associated phosphatidyl-inositol 3-kinase (PI3-K) activity is decreased [73]. Moreover, 
essential changes in skeletal muscle morphology and reduced whole-body insulin 
sensitivity were found in a female rat model of T- and DHT-induced PCOS. These 
changes included a lower amount of insulin-sensitive fibers, a higher amount of less 
insulin-sensitive muscle fibers, reduction of capillary density, glycogen synthase 
dysfunction, and lower glucose transporter 4 protein expression [60]. 
Insulin resistance is responsible for specific changes in lipid homeostasis in PCOS 
cases. Insulin-induced suppression of lipid oxidation is reduced in PCOS females. 
Interestingly, no significant changes were detected between PCOS and healthy women 
regarding peripheral lipid uptake [73]. Furthermore, IR has selective effects on adipose 
tissue in different locations; adipocytes isolated from the subcutaneous fat of lean PCOS 
patients are reported to have decreased insulin and catecholamine-stimulated lipolysis 
capacity and bigger cell size, whilst adipocytes from visceral fatty tissue show increased 
lipid oxidation rate. A higher rate of visceral lipolysis can elevate the FFA 
concentration of portal blood flow and promote the development of hepatic IR in PCOS 
[66]. Not only lipolysis but also the endocrine function of adipocytes might play a role 
in insulin sensitivity. Adiponectins are adipocyte-derived hormones that positively 





[74]. Leptin, known as the prototypical adipokine, is one protein that plays a regulatory 
role at the hypothalamic–pituitary axis. Infertility is one of the characteristics of 
congenital leptin deficiency, as leptin affects LH and GnRH secretion. In PCOS, low 
leptin serum levels are usually detected in association with hyperinsulinemia and AE 
[75]. In addition, a reduction in the adiponectin receptors of theca cells in PCOS ovaries 
(compared with normal ones) is frequently detected [76]. 
Fat accumulation may have an effect on hepatic glycogen synthase activity and 
pancreatic β-cell function. Non-alcoholic fatty liver disease and impaired glycogen 
synthase activity show a significant correlation with the prevalence of obesity in PCOS 
patients [49]. A high FFA concentration related to obesity has a negative impact on 
pancreatic β-cell insulin secretion and calcium channel distribution, which match well 
with the fat accumulation within the islets. In addition, intrapancreatic fat depots elevate 
the local amount of FFAs and trigger chronic inflammation and cytokine production 
[66]. In PCOS-related IR, chronic pancreatic islet inflammation (insulitis) could occur, 
which promotes β-cell dysfunction or apoptosis later on. Hyperinsulinemia and β-cell 
hyperplasia are the first consequences of insulitis and increased insulin demand due to 
IR, but some recent data suggest that mitochondrial dysfunction has a role in the 
pathophysiology of β-cell secretory failure [77]. Glucolipotoxicity could enhance the 
activation of reactive oxygen and nitrogen species, which leads to mitochondrial 
dysfunction and inhibition of the electron transport chain and, in turn, results in reduced 
energy production [44]. 








Figure 4. The effects of disturbed lipid metabolism on insulin resistance and 
cardiovascular complications in PCOS patients. In PCOS, impaired lipolysis results 
in free fatty acid overproduction and decreased adiponectin release. It also promotes 
pro-inflammation and thrombosis as well as IR of the liver and muscle cells. 
Atherogenic dyslipidemia due to hepatic failure, endothelial dysfunction, hypertension, 
and atherosclerosis are the end results. Abbreviations: FFA, free fatty acids; LDL-C, 
low-density lipoprotein cholesterol; CV risk, cardiovascular risk. This figure is adopted 
and modified from the article “Metabolic syndrome” [78]. 
 
 
1.3.2.1 The effects of insulin resistance on the female reproductive 
system 
Insulin regulates several signaling mechanisms that are necessary to maintain 




















dysregulates this physiological balance of signaling pathways, leading to AE and 
selective IR of the ovaries. 
At the hypothalamus–hypophysis–adrenal axis, insulin triggers GnRH and LH 
secretion pulsatility and frequency by potentiating GnRH gene transcription. Insulin 
may increase hypothalamic corticotropin-releasing hormone secretion and, possibly, 
sensitize the adrenal cortex to adrenocorticotropic hormone stimulation. At the site of 
the adrenal glands, insulin promotes androgen secretion and consecutive AE. 
The most important mitogenic effect of insulin is that it indirectly diminishes 
SHBG synthesis, which causes higher free androgen serum levels in PCOS patients. Not 
only hyperinsulinemia but also elevated concentrations of glucose and fructose are 
important indirect factors for SHBG decrease, as both monosaccharides downregulate 
hepatocyte protein synthesis by reducing hepatic nuclear factor 4-α activity [66, 79]. 
In ovarian tissue, theca cells and granulosa cells present insulin receptors and 
insulin-like growth factor-1 (IGF-1) receptors on their surfaces. The action of insulin 
was tested by direct administration of antibodies against both receptors, which led to a 
decrease in ovarian steroidogenesis [80]. Further investigations found that insulin 
modulates the activity of steroidogenic acute regulatory protein, which is a molecule 
involved in the transportation of cholesterol to the cholesterol side-chain cleavage 
enzyme and the rate-limiting enzyme of ovarian steroid synthesis. In addition to 
enhancing cholesterol side-chain cleavage enzyme activation, insulin increases the 
expression of 7-α-hydroxylase/17,20-lyase, 3-β-hydroxysteroid dehydrogenase, and 
aromatase [79]. It was recently reported that inositol phosphoglycans, which are second 
messengers in the metabolic signal transduction pathway of classic insulin receptor 
signaling, might have similar effects on the enzyme cascade of steroid genesis [79]. In 
this regard, hyperinsulinemia strongly shifts the balance towards overexpression of 
androgen-producing enzymes. Moreover, the hyperinsulinemic state represses IGF-1 
binding protein synthesis, which increases the amount of available free IGF-1 and leads 
to further enhancement of ovarian insulin signaling. Together, these complex 
mechanisms lead to ovarian selective insulin resistance, which means that the insulin 
sensitivity of the ovarian tissue is unchanged or enhanced, although metabolic IR is 





1.3.2.2 Hemodynamic consequences of insulin resistance 
In addition to its above-mentioned actions, insulin has direct hemodynamic 
effects. Insulin improves regional blood flow, increases capillary recruitment, and aids 
peripheral vasodilatation, which leads to better glucose uptake of the peripheral tissue. 
This vascular action of insulin is mediated by nitric oxide (NO) derived by the 
endothelial cells of the vasculature. In order to enhance NO production, insulin must 
cross the endothelial barrier. Although it is not well understood yet, insulin probably 
reaches the endothelial cell by receptor-mediated internalization. Some studies of obese 
and T2D patients show evidence that damage of the endothelial barrier or longer 
transport time through the capillary bed interferes with insulin-induced local blood flow 
[82, 83]. 
According to recent findings, dysregulation of endothelial nitric oxide synthase 
(eNOS) is one of the key elements of IR. Moreover, glucose and lipid toxicity promote 
the production of reactive oxygen and nitrogen species, which reduce the available NO 
concentration [84, 85]. Chronic inflammation and a prothrombotic state are additional 
consequences of the activation of reactive oxygen species, which increases the local 
level of vascular and intercellular adhesion molecules (VCAM and ICAM), C-reactive 
protein, tumor necrosis factor α, interleukin 6, and endothelin-1 (ET-1) [83]. In addition, 
chronic inflammation triggers the migration and proliferation of vascular smooth 
muscle cells, which shifts vascular reactivity towards vasoconstriction in the absence of 
a sufficient amount of NO [86]. To determine whether the metabolic or mitogen insulin-
signaling pathway coordinates NO release, endothelial cells and vascular smooth 
muscle cells harvested from healthy coronary arterioles were cultured in high-glucose, 
fatty acid, and insulin-containing media. Interestingly, mitogen signaling, including 
MAPK/ERC activation, was preserved or slightly augmented, whilst the metabolic 
pathway (PI3-K signaling) was reduced [86]. These results may prove that the 
metabolic effects of IR are responsible for the disadvantageous changes in arterial 
reactivity and that elevated CV risk is an indirect metabolic complication. 
Regarding PCOS, several studies supported the theory of compromised arterial 
reactivity; however, it is not easy to distinguish between the impacts of IR and AE. In 





significantly reduced [87]. Recent human studies showed that PCOS with or without the 
clinical features of IR and MetS elevates the level of reactive oxygen species, 
endoplasmic reticulum stress markers (GRP78, sXBP1, ATF6), and leukocyte rolling 
flux. [88]. Furthermore, a recent publication reported that 12 weeks of treatment with 
metformin improved endothelial function and significantly decreased the levels of 
ICAM-1, E-selectin, interleukin 6, and tumor necrosis factor α in PCOS patients [89]. 
Additionally, coronary artery and aortic calcification were increased in women with 
PCOS compared with healthy individuals, and age and body mass index were both 
determining factors for coronary artery calcification [90]. 
Figure 5 demonstrates a possible mechanism of vascular IR. 
 
Figure 5. The effect of insulin resistance on vascular reactivity. Normally, insulin 
signaling leads to vasodilatation by PI3-K signaling and NO production. If the amount 
of reactive oxygen species is increased, downregulation of PI3-K signaling and 
upregulation of MAPK signaling are observed. As an end effect, NO production is 
decreased and vasoconstriction occurs. Abbreviations: IRS-1, insulin receptor substrate 
1; MAPK, mitogen-activated kinase; ET-1, endothelin-1; VCAM-1, vascular adhesion 
molecule 1; PI3-K, phosphatidyl-inositol 3-kinase; Akt, protein kinase B; eNOS, 
endothelial nitric oxide synthase; NO, nitric oxide; eNOS, endothelial nitric oxide 
synthase; c-JUN, c-Jun N-terminal kinases. Adopted and modified from the article 
Phosphorylation of different 
transcriptional factors (e.g., 






Tumor necrosis factor 








“Tectorigenin attenuates palmitate-induced endothelial insulin resistance via targeting 
ROS-associated inflammation and IRS-1 pathway” [91]. 
 
 
1.3.2.3 Molecular effects of insulin resistance in PCOS 
In addition to its well-known effects on glucose homeostasis, insulin affects lipid 
and protein metabolism, cell growth, and differentiation. Insulin signaling is mediated 
by insulin receptors, which are heterotetramers of α- and β-subunits. The extracellular 
α-subunit is responsible for ligand binding, whilst the β-subunit is activated by 
autophosphorylation. The cytoplasmic β-subunits have intrinsic protein tyrosine kinase 
activity. The classic insulin receptor shares substantial structural homology with the 
IGF-1 receptor and insulin-related receptor. Hence, insulin could induce 
autophosphorylation of different receptors. It was recently revealed that this 
autophosphorylation depends on insulin concentration [92] and that the physiological 
serum concentration promotes activation of the classic receptor. 
The activated insulin receptor initiates tyrosine phosphorylation of intracellular 
substrates, like different insulin receptor substrates (IRS-1–4). Glucose uptake and 
metabolic effects are mediated by P-I3K, which then phosphorylates membrane 
phospholipids and phosphatidylinositol 4,5-bisphosphate, resulting in activation of the 
serine/threonine protein kinases (Akt) and atypical protein kinase C. These signaling 
pathways are responsible for transmembrane translocation of glucose transporter 4 or 
indirect activation of glycogen synthase. Protein synthesis and cellular nutrient sensing 
are also regulated by the PI3-K pathway via the mammalian target of rapamycin. The 
so-called mitogen pathway is regulated by the cascade of serine/threonine kinases and 
the enhancement of different MAPK kinases [93].  
Because the metabolic and mitogen effects of insulin are regulated differently, 
impairments caused by them could develop separately. Metabolic IR is the cornerstone 
of PCOS. According to several studies, protein kinase C-mediated serine 
phosphorylation of the insulin receptor, serine phosphorylation of insulin receptor 





important steps in the pathogenesis of metabolic IR in PCOS [67]. Presumably, 
downstream signaling pathways might be intact as Akt, protein kinase C, and B 
activation were unchanged in PCOS adipocytes [94]. However, a few studies suspected 
indirect regulation problems with Akt signaling [73, 93]. Increased extrinsic insulin-
independent serine phosphorylation of the classic insulin receptors seems to be specific 
to PCOS, as it is not detectable in other IR-related diseases (i.e., obesity or T2D) [66]. 
In addition to the above-mentioned defects of insulin signaling, some data suggest that 
mitochondrial dysfunction of skeletal muscle cells plays a further role in PCOS [95]. 
 
1.3.3 Cardiovascular disease  
 
The multiple metabolic complications caused by PCOS increase patients’ CV risk. 
Women with hyperandrogenic PCOS have a relative risk of coronary heart disease at 
least two times higher than that of healthy controls [96, 97]. The rate of coronary artery 
calcification, an indicator of subclinical cardiovascular disease, was found to be present 
40% of fertile-aged PCOS females (aged under 40) [98].  
The prevalence of hypertension, which is one of the earliest consequences of 
atherosclerosis and reduced compliance of the vessel wall, was reported to be present in 
65% of the premenopausal PCOS population. This proportion is even larger if the 
clinical picture involves IR, AE, and obesity or if patients are already in menopause 
[99]. 
Altered intima–media thickness of the vessel is considered to be a noninvasive 
marker of coronary and cerebrovascular events [100]. Premature atherosclerosis and 
higher intima–media thickness values (compared to healthy individuals) are frequently 
present in premenopausal PCOS women [100, 101]. This early stage of atherosclerosis 
in PCOS is often associated with elevated LDL serum levels or obesity [97]. 
Further cardiovascular abnormalities of PCOS patients include decreased cardiac 
systolic flow velocity, diastolic dysfunction, increased vascular stiffness, and 





way to evaluate left ventricular function in PCOS patients, but the results are highly 
dependent on image quality, the assumption of left ventricular geometry, and the 
experience of the investigator. Some studies found evidence of a connection between 
early left ventricular impairment when mitral inflow deceleration time, isovolumetric 
relaxation time, and diastolic function were altered in the PCOS group [102]. Systolic 
blood flow velocity was also found to be decreased in PCOS, with an inverse 
correlation between systolic outflow parameters and fasting insulin levels [103].  
Chronic activation of the sympathetic nervous system could lead to vascular 
dysfunction and hypertension. In PCOS, activation of the sympathetic nervous system 
and IR is a complex mechanism that is related to obesity. In PCOS patients, impairment 
of the sympathetic nervous system was demonstrated by an exaggerated systolic blood 
pressure response to exercise and delayed heart rate recovery [104]. Another study 
demonstrated that a high density of catecholaminergic nerve fibers is present in the 
ovaries of women with PCOS, which correlates with skeletal muscle and adipose tissue 
results [66]. 
 
1.3.3.1 The role of endothelial dysfunction 
In PCOS, endothelial dysfunction is the source of further cardiovascular 
complications, and its severity is proportional to the level of androgens and IR. 
Hyperinsulinemia-induced endothelial dysfunction and hypertrophic remodeling occur 
due to its effects on vascular endothelial and smooth muscle cells as well as ET-1 
production. ET-1 release is reported to be significantly increased in PCOS females, and 
this is also a sign of oxidative stress and altered vascular compliance [105]. Disturbed 
insulin-stimulated eNOS activation and NO release appear to negatively influence 
capillary network expansion, resulting in impaired microcirculation and blood flow 
regulation in metabolically active tissues. 
Not only hyperinsulinemia but also an elevated level of circulating FFAs and 
chronic inflammation could enhance endothelial impairment by altering activation of 
the renin–angiotensin–aldosterone axis. The vascular effects of angiotensin II are 





effects. Both receptors are expressed on the endothelial surface, but receptor subtype 1 
is responsible for the well-known vasoconstrictor effects. PCOS rodent models revealed 
that reduced endothelial NO bioavailability, impaired insulin signaling, and IR are 
promoted by subtype 1 activation [106, 107]. Some recent clinical trials were able to 
prove the beneficial effects of selective angiotensin receptor subtype 1 blocking agents 
in PCOS females, such as improved cardiometabolic risk due to increased insulin 
sensitivity and prevention of T2D [107]. The effects mediated by angiotensin receptor 
subtype 2 include vasodilation and augmented insulin-mediated glucose disposal. These 
facts suggest a possible imbalance between the two receptor signaling mechanisms in 
PCOS, which could be indirectly improved by inhibition of angiotensin receptor 
subtype 1 [108]. 
Hormonal modulation failure of vascular reactivity plays an important role in 
impaired endothelial function. The two main effects of estrogens are eNOS 
phosphorylation due to activation of the PI3-K/Akt pathway and increased eNOS 
mRNA expression. In transgenic mice, the activation of estrogen receptor α was 
responsible for eNOS protein production [109]. In addition, estrogen regulates vascular 
endothelial growth factor production (via estrogen receptor α) in coronary circulation. 
These findings align with the flow-mediated vasodilatation results of healthy, 
premenopausal, and estrogen-deficient postmenopausal women [110].  
Regarding the effects of androgens, the tissue-specific distribution of two key 
enzymes, aromatase and 5-α-reductase, must be taken into consideration. DHT is pure 
androgen, but T could be converted into estrogen and activate estrogen receptor α. 
Furthermore, T has complex vascular effects: it could relax coronary arteries by opening 
the large-conductance, calcium-activated potassium channels and up-regulating 
cyclooxygenase-2 activity, which in turn leads to increased prostacyclin formation 
[109]. The vascular effects of T may be gender-dependent, as flow-mediated 
vasodilatation was reduced in female-to-male transsexuals after administration of high 
concentrations of androgen. Animal studies of sexual transition suggest that T has a 
negative effect on eNOS-mediated vascular responses [111]. Androgens can also induce 
vasoconstriction by modulating the production of ET-1 or enhancing the production of 
arachidonic acid intermediates, including thromboxane A2 and 20-





women, AE correlates well with ET-1 levels and subclinical cardiovascular risk [109, 
112]. 
It was recently revealed that the levels of adipocytokines, such as visfatin, 
vascular endothelial growth factor, and matrix metalloprotease, can be used as specific 
indicators of endothelial dysfunction. Visfatin has insulin-mimicking effects and lowers 
blood sugar values. According to recent data, lower concentrations were found in PCOS 
females compared to controls with a similar body mass index. Increased vascular 
endothelial growth factor production is an indicator of chronic mild inflammation and is 
related to impaired vascular reactivity. Increased metalloprotease 9 concentrations 
predict excessive CV risk and extracellular matrix remodeling [113].  
 
1.4 Vitamin D  
 
VD is a fat-soluble vitamin that also acts as a steroid hormone. As a steroid 
hormone, VD is involved in mineral homeostasis, has immunomodulatory effects, and 
seems to have a protective role against MetS and cardiovascular disease.  
VD is produced non-enzymatically under the skin upon exposure to ultraviolet 
sunlight, but dietary sources are important for a sufficient supply. Cytochrome p450 
enzymes, namely CYP2R1, CYP27B1, CYP24A1, and CYP27B1, are involved in the 
metabolism of VD, which takes place in the liver and kidney. According to some 
estimations, more than 200 genes, most of which are responsible for cellular 
proliferation, differentiation, apoptosis, and angiogenesis, are directly or indirectly 
controlled by 1,25-hydroxyvitamin D. VD receptors (VDR) are reported to be present in 
brain, prostate, breast, colon, and pancreas tissue as well as in immune cells. Normal 
serum levels of VD are considered to be within the range of 30–100 ng/ml. Figure 6 
shows the specific effects of VDR activation in different tissues. 
VD insufficiency is a comorbidity that affects approximately 50% of the whole 





in 67–85% of PCOS women. VDD could influence PCOS through hormonal and gene 





Figure 6. Effects of VDR activation in the human body, in special regard to 
cardiovascular risk factors. A. VDR activation in target cells. In the nucleus, VDR 
and retinoid X receptor form a heteromer, which promotes the transcription of several 
genes. B. VD-mediated effects in the heart and blood vessels. VD promotes vascular 
repair, improves flow-mediated endothelial relaxation, and modulates cardiac 
contractility. Further organ-specific positive effects on cardiovascular risk factors are 
shown below. Abbreviations: VDR, vitamin D receptor; RXR, retinoid X receptor; NO, 
Cardiac effects: 
 Antihypertrophic effects 
 Regulation of extracellular 
matrix turnover 
 Regulation of calcium 
influx 
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nitric oxide; CV risk, cardiovascular risk. Adopted and modified from the article 
“Vitamin D and cardiovascular disease prevention” [116]. 
 
1.4.1 Vitamin D and cardiovascular complications 
 
The paracrine and autocrine actions of VD seem to be important for 
cardiovascular health. Cardiac inflammation, oxidative stress, energetic metabolic 
changes, cardiac hypertrophy, and alteration are just some of the complications 
observed in cases of VDD.  
Left ventricular hypertrophy and negative inotropic changes were reported to be 
associated with low VD serum levels. In a rat model of T2D-induced left ventricular 
hypertrophy, VD successfully improved left ventricular mass by reducing TNF-α 
expression and inhibition of nuclear factor-kappa beta expression. VDD-induced 
chronic hypocalcemia could be a cause of dilated cardiomyopathy, which confirms the 
role of VDD. The ratio of serum 1,25(OH)2D3 to parathyroid hormone could be a 
predictor of chronic heart failure and cardiovascular disease [117]. Not only endocrine 
but also genetic disorders in VDR signaling could lead to impairment in cardiac 
structure and function. Both whole-body VDR knockout and myocyte-specific VDR 
knockout mice exhibited reduced cardiac pump function due to cardiac remodeling and 
a higher prevalence of cardiac steatosis [118]. Another study with VDR knockout mice 
revealed significantly higher expression of collagen 1α1, collagen 3α1, matrix 
metalloproteinase 2, and osteopontin, which favor endothelial–mesenchymal transition 
and mediate cardiac fibrosis. If VD treatment is applied in isoproterenol-induced 
cardiomyopathic rats, the lower level of matrix metalloproteinase activity and 
diminution of endothelial cell transition are detected [119]. Some studies revealed that 
VDD could negatively influence postinfarction complications and cardiac remodeling in 
patients with myocardial infarction. 
VD modulates the renin–angiotensin–aldosterone system and has direct effects on 





[120]. In obesity cases, perivascular adipose tissue affects smooth muscle contractility 
and endothelial function through local production of paracrine factors. According to 
some data, in VDD cases, the perivascular adipose tissue fails to suppress the enhanced 
contractile response of resistance arteries because angiotensin-induced contraction of 
mesenteric arteries was significantly increased. In a diabetic mice model of 
atherosclerosis, VDR and retinoid X receptor agonists (RXR) reduced atherosclerotic 
plaque formation and oxidative stress. Moreover, lower expression of VDR was 
detected within atherosclerotic plaque, which combined the expression alterations of 
VDR on M1 and M2 macrophages. VDD is followed by macrophage polarization (M1 
versus M2) and intraplaque cholesterol efflux, which supports the role of VD in the 
early steps of atherosclerosis [117, 121]. Arterial aging and stiffness, atherosclerosis, 
and vascular calcification could also be related to low VD levels in peripheral arterial 
disease [120, 122, 123]. 
 
1.4.2 Vitamin D and insulin resistance 
 
A low VD serum level seems to be a risk factor for the development of IR and 
diabetes (both type 1 and 2) by affecting insulin sensitivity or β-cell function. The 
prevalence of VDD is reported to be at least two times higher among patients with T2D 
compared to the healthy population. In T1D, the onset of disease often co-occurs with 
low VD serum levels, and the latter is reported to be a risk factor affecting the severity 
of later complications [124]. 
Genetic polymorphism of VDR, VD binding protein, and VD 1α-hydroxylase are 
responsible for inherited risk of IR. Several VDR polymorphisms have been found since 
the early 1990s, including Fok1, Apa1, Bsm1, and Taq1. Results from the Asian 
population indicate that Bsm1 polymorphism is associated with a significantly higher 
prevalence of T1D in adults. Another study from Germany suggested that a certain 
combination of Bsm1/Apa1/Taq1 polymorphisms increased the risk for T1D. Some 
electrophoretic variants of VD-binding proteins are suspected to promote prediabetes 





VD-binding protein gene were reported to increase the prevalence of prediabetes in 
adults [126]. 
VD signaling pathways maintain balance in the inflammatory response by 
regulating both innate and adaptive immune reactions. On one hand, 1,25-
dihydroxyvitamin D inhibits the adaptive immune response by affecting the capacity of 
antigen-presenting cells, which enhance T lymphocyte activation, proliferation, and 
cytokine secretion. On the other hand, 1,25-dihydroxyvitamin D regulates the innate 
immune system by modifying the maturation and differentiation of macrophages and 
dendritic cells and diminishing cytokine production. If this equilibrium of immune 
regulation is disturbed, β-cell degradation may occur due to overproduction of cytokines 
like interleukin-2 and 12 (which stimulate T-helper 1 cell development), interferon-γ, 
and tumor necrosis factor α (which stimulate inflammation) [126]. Moreover, 
macrophages and dendritic cells are able to produce 1,25-dihydroxyvitamin D with their 
own 1α-hydroxylase enzymes. Liver resident macrophages or Kupffer cells express the 
highest amount of VDR among non-parenchymal VDR-expressing cells. Their 
overactivation in a diet-induced obesity mice model triggered circulating macrophage 
recruitment in the liver, which led to chronic inflammation, impaired hepatic insulin 
sensitivity, and non-alcoholic fatty liver disease [127] 
Insulin secretion from β-cell is reported to be directly stimulated by VD, but 
optimal calcium and parathyroid hormone levels are also essential. In a VDD rat, 
glucose-stimulated insulin secretion was significantly disturbed if hypocalcemia was 
also present. Parathyroid hormone not only controls the activation of 1α-hydroxylase 
but also decreases glucose uptake in the liver, muscle, and adipose cells. The pro-
diabetic effect of parathyroid hormone is due to the inhibition of translocation of 
glucose transporters 1 and 4 in hepatic and skeletal muscle cells. As 1,25-
hydroxyvitamin D suppresses parathyroid hormone production at the transcription level, 
higher parathyroid hormone plasma levels are secondarily connected to either an 







1.4.3 Vitamin D and female fertility 
 
It has been recently demonstrated that VD has multiple regulatory roles in 
reproductive tissue. Granulosa cells, the cumulus oophorus in human ovaries, the 
decidua and placenta, endometrium, and the pituitary gland all express VDR. In 
addition, human endometrium cells and the placenta exhibit 1α-hydroxylase activity.  
VD regulates the expression of several cytochrome P450 enzymes involved in 
ovarian steroidogenesis. In vitro studies with human ovarian cell lines showed that 
calcitriol stimulated progesterone synthesis by 13%, estradiol synthesis by 9%, and 
estrone synthesis by 21% [128]. A study involving human granulosa cells ended with 
similar results; mRNA expression and activity of the enzyme 3β-hydroxysteroid- 
dehydrogenase were significantly upregulated after administration of calcitriol [129]. 
The mechanism of this regulation is not yet clear, but it was recently revealed that a VD 
response element is located in the promoter region of the aromatase enzyme, which is 
the key enzyme in the aromatization of androgens to estrogen in ovarian tissue. 
Calcitriol was also shown to have a direct effect on the signal transduction of 
adenosine-monophosphate-activated protein-kinase-induced phosphorylation, which is 
an essential step in enzyme expression associated with steroidogenesis [130]. In VDR 
and 1α-hydroxylase knockout female mice, infertility was found due to the combination 
of disturbed follicular maturation, reduced aromatase activity, and estrogen and 
progesterone deficit. In human granulosa cell lines from small primordial follicles (one 
of the characteristic features of PCOS), the level of VD in follicular fluid was two times 
lower compared to cells from normal-sized follicles. Moreover, VDR expression is 
significantly higher in the nuclei of granulosa cells from large follicles [129]. It seems 
that VD supports the selection and growth of follicles by adjusting L-type calcium 
channels and downregulating gap junction proteins in maturing follicles [131]. 
As was previously mentioned, the serum AMH level reflects the number of 
growing ovarian follicles and could be used a possible biomarker of PCOS. In human 
granulosa cells, calcitriol was not only able to decrease the level of AMH in small 
follicles but also reduced the expression of its highly specific receptor (type II) and the 
FSH receptor in vitro [129]. 
During pregnancy, calcium transport between trophoblasts and the endometrial 





reported to be important for the sexual steroid synthesis of trophoblast cells and 
modulation of uterus tone and contraction in a calcium-dependent manner. Successful in 
vitro fertilization is more likely if VD serum levels are kept within a high normal range 
(at least 30–45 ng/ml) [132].  
 
1.5 Evaluation of rodent models for PCOS 
 
During the last three decades, many animal models have been tested to explore 
PCOS. The limitations of these models are mostly due to differences in ovulation 
patterns, released hormone profiles, sensitivity to hormones, behavioral characteristics, 
and organ anatomy. In addition, unlike humans, animals in nature very rarely develop 
AE and PCOS, although a PCOS-like syndrome with ovulation disorder is present in 
rats, pigs, cows, dogs, and monkeys [133]. Interestingly, in these animals, a 
hyperandrogen state is seldom part of the syndrome, but in primates, endocrine 
disorders are often involved in PCOS. In naturally hyperandrogen female rhesus 
monkeys, reduced fertility is combined with significantly increased serum levels of 
androstenedione, 17-hydroxyprogesterone, estradiol, LH, AMH, and cortisol [59]. 
PCOS-like animal models could be induced by androgens, including T 
propionate; dihydrotestosterone; dehydroepiandrosterone; or other hormonal agents, 
such as estradiol valerate, glucocorticoid, human chorionic gonadotropin, or AMH [60, 
134-137]. Other studies used endocrine disruptors like letrozole (a P450 aromatase 
inhibitor) and bisphenol A to induce PCOS [138, 139]. Although such interventions and 
continuous light exposure could induce PCOS in rats [140], almost all of these non-
hormonal methods were unable to reproduce dysfunctional ovulatory patterns and 
ovarian morphological changes such as a decreased amount of corpus luteum and an 
elevated number of antral and cystic follicles. Nevertheless, androgens are essential for 
inducing a hyperandrogenic state, as drugs with an estrogenic effect showed no or low 
impact on circulating androgen levels [133, 141]. Hence, hormonal interventions using 
androgens seem to be the most appropriate method for inducing a PCOS-like phenotype 





In vivo rat and mouse models of human PCOS have several advantages over 
models involving other animals. First, these rodents possess stable genetic backgrounds, 
are easy to handle and maintain, and have shorter reproductive lifespan and generation 
times. Their short estrous cycles (4–5 days in both rats and mice) allow for fast 
evaluation of developing disturbances. In addition, the feasibility of genetic 
manipulation and affordability of rats and mice make them ideal for in vivo endocrine 
investigations. Their hormonal regulation of reproduction, hypothalamic–pituitary axis, 
and process of ovarian follicle development show well-conserved evolutionary patterns, 
similar to those in primates. In addition, rat and mice models demonstrate all the well-
described hormonal and metabolic features of PCOS, including hyperandrogenism, 
elevated LH levels, ovulatory abnormalities, polycystic ovarian morphology, and 
altered insulin sensitivity [60, 142]. 
According to a great number of studies, timeframe and length of exposure to the 
chosen agent have a great influence on PCOS-like phenotypes. Postnatal treatment with 
androgens induces typical human PCOS features in rodents. If a single proportionate 
dose of T is administered to rats (1–5 days) and mice (1–3 days) after birth, the animals 
fail to ovulate later in adulthood. The best PCOS phenotype results were achieved with 
chronic treatment of T or its active metabolite, DHT (8–12 weeks) in adolescent animals 
(21 days old). In such cases, all the major PCOS symptoms are manifested, including 
estrus acyclicity, anovulation, polycystic ovaries, hyperandrogenism, and IR. 
Interestingly, if an excess of androgens arises during pre-adolescent (15–25 days old) 
female rats, none of the specific characteristics of PCOS appear [142].  
Fetal or prenatal exposure to androgens led to conflicting results in rodents, but 
not in non-human primates. In rhesus monkeys, fetal encounter with T in the early to 
middle phase of gestation results in the most suitable phenotype for human PCOS 
models [38]. Abbott suggested a “two hit” theory regarding the manifestation of PCOS 
in early adulthood. The first “hit,” which is essential for later onset of AE, should occur 
in the prenatal phase. It was recently reported that the level of T in the umbilical vein of 
female infants born to hyperandrogen PCOS mothers is significantly elevated. Although 
there is currently no data regarding how many of these infants had PCOS as adults, the 





Abbott’s theory, hyperinsulinemia is the second “hit,” which is facilitated by 
dysfunctional adipose-tissue-dependent lipid homeostasis and postnatal obesity. 
In summary, previously reported data support the possibility of different 
vulnerable phases of AE after promoting the development of PCOS during adulthood. 
Rodent models are suitable for studying postnatal AE, as they are easy to reproduce and 
provoke hormonal and metabolic changes similar to those of human PCOS phenotypes. 
 
1.6 Connections between the vascular effects of PCOS 
and vitamin D supply 
 
The results of human studies involving subjects with PCOS showed a possible 
inverse association between serum VD levels, IR, and vascular function, but the 
potential beneficial vascular effects of VD supplementation are still under debate [115]. 
It was previously reported that VD supplementation improved the acetylcholine-
induced relaxation of abdominal aorta and skeletal muscle resistance arterioles in 
female PCOS rats. The results from the same model also indicated that VD 
supplementation had a positive impact on the disadvantageous vascular and ovarian 
effects of nitrative stress [144-146]. Furthermore, noradrenalin-induced vasoconstriction 
in thoracic aorta rings from DHT-treated animals and VD-deficient animals was 
significantly enhanced and combined with impaired NO-dependent vasorelaxation. In 
this case, calcitriol administration was able to improve vascular relaxation capacities, 
but this effect was reduced by prostanoid-dependent vasoconstriction [145]. 
According to some studies, in hyperandrogen PCOS cases, vascular remodeling 
resulted in more rigid, less adaptive vessels, which was mostly interpreted as the first 
step towards a hypertensive state. If VD supplementation was applied to hyperandrogen 
PCOS rats, the negative effects of eutrophic remodeling were less pronounced [147].  
Not only arterioles but also veins are affected by VDD, which suggests that VD 
plays a complex regulatory role in the vascular system. In rats with AE PCOS, veins 






The impacts of VDD and supplementation on remodeling and functional changes 
in coronary resistance arterioles in hyperandrogen PCOS cases have not yet been 
studied in parallel. Thus, we aimed to reveal the possible positive influence of VD 
supplementation and specific details about the damage to coronary resistance arterioles 






2 Aim of the study  
 
Our aim was to create a new, easily reproducible hyperandrogen PCOS rat model 
to explore the use of transdermal T treatment. Rodent models are frequently used to 
study PCOS, but as mentioned previously, this is the first to induce AE with the use of a 
transdermal androgen hormone. We also aim to create a chronic model that could 
reproduce all the well-known reproductive, metabolic, and vascular alterations of 
PCOS.  
Considering that PCOS and VDD are frequent comorbidities with similar 
cardiometabolic complication profiles, we aimed to examine their separate and joint 
impacts on the severity of metabolic complications, IR, and early alterations of the 
function of coronary resistance arteries. 
The goal of the study was to investigate early and typical changes in coronary 
biomechanics that may put PCOS and VDD women at higher risk of cardiovascular 
disease. We assumed that IR is of great importance in both diseases due to its effects on 
functional disturbances, such as reduced dilatation capacity or coronary wall 
remodeling. It was also relevant for us to show whether there is any kind of interaction 










Transdermal T gel (Androgel 1% from Lab. Besins International S.A, Paris, 
France) was used to induce a hyperandrogenic state. Cholecalciferol suspension 
(Vigantol oil 20,000 IU/ml from Merck/Merck Serono12, Mumbai, Maharashtra, India) 
was applied for oral VD supplementation. We used a normal Krebs-Ringer solution for 
in vitro studies, which contained the following (in mmol/l): NaCl 119, KCl 4.7, 
NaH2PO4 1.2, MgSO4 1.17, NaHCO3 24, CaCl2 2.5, glucose 5.5, and EDTA 0.034. To 
produce smooth muscle relaxation, we used a Ca-free Krebs solution containing the 
following (in mmol/l): NaCl 92, KCl 4.7, NaH2PO4 1.18, MgCl2 20, MgSO4 1.17, 
NaHCO3 24, glucose 5.5, EDTA 0.025, and EGTA 2. Solutions were kept at a fixed 
temperature (37 ºC) to stabilize pH they were bubbled with a gas mixture of O2 (20%), 
CO2 (5%), and N2 (75%). U46619 (a thromboxane A2 receptor agonist) was purchased 
from TOCRIS Bio-Techne (Bristol, UK), and adenosine (Adenocor) was purchased 
from Sanofi-Aventis (Madrid, Spain). Human-recombinant insulin (Actrapid pentafill 
100 IU/ml) from Novo Nordisk was used for in vitro vascular tests. All chemicals were 
freshly prepared in normal Krebs solution on the day of the experiment.  
For anesthesia, 45 mg/kg of intraperitoneal Nembutal (Phylaxia-Sanofi, Budapest, 




In total, 46 adolescent (21–28 days old) female Wistar rats weighing 90–110 g 
were provided by the Animal Facility of Semmelweis University in agreement with 
Charles River. The animals were supplied ad libitum with tap water and with normal or 
VD-deficient food (see below). Four to five rats were housed together with a constant 





(56%). Starting from the 6th week, daily vaginal smear examinations were performed to 
assess ovulatory cycle changes. No medical or toxic complications were observed 
during the eight-week treatment period. The investigation conforms to the Guide for the 
Care and Use of Laboratory Animals published by the US National Institutes of Health 
(8th edition, 2011) and the Hungarian Law on Animal Care (XXVIII/1998). The 
Institutional Animal Care Commission and Hungarian authorities accepted the protocol 
(PEI/001/820-2/2015). 
 
3.3 Chronic treatment 
 
The study lasted eight weeks for each group. Rats were randomly selected into 
four groups. Twenty-four of the animals received a complete normal diet (ssniff 
Germany, SM rat/mouse complete diet containing 1,000 IU/kg vitamin D3). To ensure 
optimal VD serum levels (serum 25-hydroxicholecalciferol of 30ng/ml), the above-
mentioned animals received oral VD supplementation (see below). Twelve of the VD-
supplemented rats composed the VD-supplemented, transdermal T-free group (VD+/T-, 
n = 12). The other 12 animals received regular transdermal T treatment as described 
below (VD+/T+ group, n = 12). To model VDD, 22 animals were put on a VD-free diet 
(ssniff Germany, EF rat/mouse complete VD-free diet containing < 5 IU/kg of vitamin 
D3). Additional VD intake was excluded throughout the protocol period, which ensured 
severe VDD during the course of the study. Half of the animals were left without 
additional T treatment (VD-/T- group, n = 11), while the other half were given 
transdermal T (VD-/T+ group, n = 11).  
Body weight was measured five times a week throughout the full study period. 
Body mass gain ratio (%) was calculated (final bodyweight/initial bodyweight *100%). 
Oral cholecalciferol administration proceeded as follows: at the beginning of the second 
week, 500 IU of vigantol oil was administered per os as a loading dose, and from the 
fourth week on, cholecalciferol was provided weekly up to 3000 NE/kg body weight 
(based on regular body weight measurements) to reach a higher range of normal VD 





Back skin was regularly shaved before transdermal T treatment. T gel was applied 
five times a week from the second day of treatment. The dose was 0.033 mg/g body 
weight[148], which ensured close to tenfold elevation of plasma T levels in treated 
female animals (see Table 1). 
 
3.4 Oral glucose tolerance test and homeostatic 
assessment for insulin resistance 
 
The oral glucose tolerance test (OGTT) was performed on the sixth week of 
treatment. After overnight fasting, a loading dose of 30% glucose solution (2g/ 
bodyweight kg glucose) was administered per os through a gauge [149]. Blood sugar 
levels were measured at 0’-60’-120’ using a Decont Personal Accu-check (77 
Electronics, Budapest, Hungary). Serum insulin levels at 0’-120’ were detected using an 
enzyme-linked immunosorbent assay (ELISA) from Merck/Merck Millipore 
(Darmstadt, Germany/Budapest, Hungary). Homeostatic assessment for insulin 
resistance (HOMA-IR) was calculated as fasting plasma insulin (in milliunits per liter) 
× fasting plasma glucose (in millimoles per liter)/22.5. 
 
3.5 Sexual steroid, leptin, and vitamin D plasma levels 
 
Blood samples were taken on the eighth week of treatment from the tail vein. 
Serum samples were obtained and analyzed with high-performance liquid 
chromatography. The 5-dihydrotestosterone, 5-hydroxycholecalciferol, progesterone, 
and T levels were evaluated using a Flexar FX-10 ultra-performance liquid 
chromatograph coupled with a Sciex 5500 QTRAP tandem mass spectrometer operated 
in the positive electrospray ionization mode. DHT, 5-hydroxycholecalciferol, 





separation was performed using an octadecyl silica stationary phase. Detection was 
carried out with scheduled multiple reaction monitoring. A serum sample of 100–400 
µL was spiked with 10 µL of internal standard solution (containing 200 ng/ml 13C3-T, 
5 ng/ml D5-estradiol, and 2.5 µg/ml D6-25-hydroxycholecalciferol in acetonitrile) and 
diluted with 350–650 µL water and 250 µL methanol to obtain a 1 ml mixture, which 
was vortexed and extracted twice with 1 ml of ethyl-acetate. The organic phases were 
combined and evaporated to dryness under a stream of nitrogen. To assess DHT, 5-
hydroxycholecalciferol, progesterone, and T levels, the residue was dissolved in a 50:50 
v/v % mixture of water and methanol and was submitted for analysis [150]. Calibration 
was performed using the Chromsystems MassChrom® Steroids 6PLUS1® Multilevel 
Serum Calibrator Steroid Panel 2 (Abl&E-Jasco Magyarország Kft, Budapest, Hungary) 
with ranges of 0.47–1.34 ng/ml, 0.04–4.94 ng/ml, 0.17–25.6 ng/ml, and 0.05–11.8 
ng/ml for DHT, progesterone, and T, respectively. Then, 25-hydroxycholecalciferol was 
calibrated using aqueous solutions containing 1.0–50 ng/ml 25-hydroxycholecalciferol. 
All calibrators were treated in the same way as test samples [150, 151]. 
 
3.6 Vaginal smear examination and ovarian 
morphology 
 
Starting from the sixth week, for 14 days (until the end of the eighth week of 
treatment), daily vaginal smear examinations were performed to assess changes in the 
estrus cycles of the animals. Samples were dyed with 1% methylene blue solution. After 
microscopic analysis of the dominant cell types, a 4–5-day-long ovulatory cycle with at 
least three of four subsequent stages of the estrus cycle was regarded as normal. 
The ovarian weight of each animal was measured upon termination of the study. 
Ovaries were collected for histological examination and fixed in formaldehyde solution. 
Four-µM longitudinal and serial sections of the ovarium were produced, and every tenth 
section was stained with hematoxylin–eosin. Representative samples of each treated 
group (n = 6) were analyzed to detect polycystic ovarian morphology. The total number, 





were measured with AxioVision Panoramic Viewer software (3DHISTECH Ltd., 
Budapest, Hungary). 
 
3.7 Transthoracic echocardiography and invasive 
arterial blood pressure measurement 
 
Transthoracic echocardiography was performed at the eighth week of treatment 
under pentobarbital anesthesia (intraperitoneal injection of 40 mg/kg). For this purpose, 
we used a SONOS 5500 ultrasound machine (Hewlett Packard) equipped with a high-
frequency linear transducer (5–15 MHz). Long-axis B-mode images of the left ventricle 
were obtained to calculate end-diastolic volume and end-systolic volume from the left 





/3LVLs, respectively (in the formulae, d and s stand for diastole and systole, 
respectively). Based on these parameters, the ejection fraction was calculated as 
100(end-diastolic volume – end-systolic volume)/end-diastolic volume. Left ventricular 
short-axis echocardiograms were taken at the level of the papillary muscles to determine 
diastolic left ventricular wall thickness. In order to assess fractional shortening, short-
axis images were used to measure left ventricular internal diameters in the diastole and 
systole (LVIDd and LVIDs, respectively). These parameters allowed for calculation of 
fractional shortening using the following formula: 100 (LVIDd-LVIDs)/LVIDd [152, 
153].  
Arterial blood pressure was invasively measured through an internal carotid artery 
catheter and was performed at the beginning of the experiment. Carotid artery catheter 
insertion was performed under aseptic conditions with the help of general surgical 







3.8 Pressure arteriography of coronary arterioles 
 
During the eighth week of treatment, animals were anesthetized as mentioned 
above. Under anesthesia, we performed heart ultrasound and invasive blood pressure 
measurement through carotid artery cannulation. Then, the chest was opened in order to 
extract the heart, which was perfused with a non-heparinized normal Krebs solution for 
two minutes. Heart weight was measured, followed by micropreparation of a coronary 
arteriole segment from the intramural network of the left anterior descendent coronary 
artery with an in vivo outer diameter of 100–150 µM. The coronary arteriole was 
microcannulated in normal Krebs solution in an organ chamber filled with saline and 
then oxygenized at a fixed temperature of 37 ºC. The microcannulas were connected to 
the servo pumps (Living Systems). Under no-flow conditions, the arteriole was 
intraluminally pressurized at 50 mmHg and extended to its normal in vivo length. The 
setup was positioned in the light path of an inversed Leica microscope to allow for 
evaluation of changes in the inner and outer diameters of the arteriole. With the aid of a 
digital histologic Leica video camera (DFC 320) and Leica QWin software, magnified 
pictures of the arteriole were obtained. Analysis of the vessel pictures was performed 
offline with the help of a Leica QWin image analyzing program. 
The arteriole was allowed to equilibrate in oxygenized normal Krebs solution at a 
fixed pressure (50 mmHg) and temperature (37 ºC) for 30 minutes. During this 
incubation period, the arteriolar segments developed spontaneous tone. Their steady-
state diameter was measured in this state. Pressure-diameter profile curves were 
obtained by training (0-150-0-150 mmHg intraluminal pressure) and performing 
fraction elevation (10 mmHg) of the intraluminal pressure from 0 mmHg to 150 mmHg. 
At the end of the 10-minute incubation period, when 50 mmHg intraluminal pressure 
was achieved, the resting diameter under intraluminal pressure was re-measured. 
As the next step, an increasing dose of insulin (insulin concentrations of 30 
mIU/ml, 100 mIU/ml, 300 mIU/ml, 600 mIU/ml; 1 IU = 0.035 mg insulin) was added to 
the bath and segments were incubated for eight minutes. After registration of each dose 
response, the drug was washed out from the bath of the organ chamber with a slow 





The vasoconstrictor biomechanical properties of the vessel were tested by a single 
high dose (10
-6
 M) of thromboxane A2 receptor agonist (U46619). After five minutes of 
incubation, intraluminal pressure was gradually increased in 10 mmHg increments from 
0 to 150 mmHg and alteration of the inner and outer diameters was registered. After 
resting for 10 minutes under 50 mmHg intraluminal pressure, the inner and outer 
diameters were recorded again. 









 M), a potent coronary relaxant agent, was added to the organ bath. Each dose 
was equilibrated for a three-minute period and changes in diameter were recorded. 
The maximal smooth muscle relaxant potential of the vessel was evaluated by 
changing the organ chamber’s solution to a calcium-free Krebs solution, which was 
both heated and oxygenized. After 20 minutes of incubation, the passive biomechanical 
properties of the vessel were examined based on changes in the inner and outer diameter 
under gradual elevation of intraluminal pressure (0 mmHg to 150 mmHg). The 
maximum relaxant diameters of the segments were obtained in calcium-free Krebs 
solution (warmed and oxygenized).  
 
3.9 Biomechanical calculations 
 
As mentioned above, the inner and outer diameters of the vessel were measured. 
The inner and outer radii were computed based on the diameter results (Ri = inner 
diameter/2, where Ri is the inner radius and Ro = the outer diameter/2, where Ro is the 
outer radius). Full contraction of the segment (TFull) is described by the following 
equation: TFull = 100*(Rcafree-RU46619)/Rcafree (%), where Rcafree is the radius measured in 
calcium-free solution and RU46619 is the measured radius if thromboxane A2 agonist was 
added to the organ chamber. Spontaneous (myogenic) tone was computed as follows: 
TnKR = 100*(Rcafree-RnKR)/Rcafree (%), where RnKR is the radius of the coronary segment 
in normal Krebs solution. Adenosine-induced relaxation of the coronary arteriole 
segments was calculated with the help of the radius parameter (RAde), which was 





chamber as follows: TAde = 100 * (RAde – Ru46619)/Rcafree (%). Tangential stress was 
calculated according to the Laplace equation: Tg stress = P*Ri nKR/hnKR, where Tg stress is 
the tangential (circumferential) wall stress, P is the intraluminal pressure, Ri is the inner 
radius, and hnKR is the wall thickness in normal Krebs solution. Wall thickness was 
calculated based on the following parameters: h = Ro – Ri. The circumferential 
incremental elastic modulus was computed with the following equation: Einc= (dP/dRo) 






), where Einc is the incremental elastic modulus and dRo is the 
change in the outer radius in response to a change in dP upon intraluminal pressure. A 
cross-sectional area was calculated based on the inner and outer radii in a calcium-free 
solution: Acs = (Ro cafree
2
 – Ri cafree
2
) * π. The remaining tone in insulin was expressed as 
a percent of the actual radius as a percent of passive (fully relaxed) radius: TIns = 100 * 
(Rcafree-RIns)/Rcafree (%), where RIns is the radius of the coronary arteriole if insulin was 




For histological examination, an intact and neighboring segment of the same vessel was 
removed from the coronary network. At first, the segment was fixed with formaldehyde 
and stained with hematoxylin-eosin and resorcin-fuchsin. Microscopic and 
morphometric pictures were taken, and elastic fiber density measurements were 
conducted on the scanned sections (Panoramic Viewer, 3DHISTECH Ltd., Budapest, 
Hungary) under identical conditions. RGB pictures of resorcin-fuchsin-stained segments 
were analyzed with Leica Qwin image analysis software. The software allows for 
identification, selection, and subtraction of structures of images based on spectrums of 
R (red), G (green), and B (blue) including 126 tones of red, 126 of green, and 126 of 
blue. The likelihood of separating structures within their limits is greater if higher 
numbers of red, green, and blue tones and combinations thereof are present in the 
studied tissue. Elastic fiber density was analyzed as follows: as the magenta color of the 
resorcin-fuchsine stain suppresses green, RGB green intensities (0–255) were measured 






3.11 Immuno-histochemistry of coronary arterioles 
 
Paraffin-embedded tissue sections were stained against insulin receptor beta and 
VDR using the BenchMark ULTRA Automated IHC/ISH slide staining system 
(Ventana Medical Systems, Inc., Tucson, AZ, USA) with monoclonal mouse anti-
insulin receptor beta (Santa Cruz Biotechnology, Dallas, TX, USA) and polyclonal 
rabbit anti-VDR (Abcam, Cambridge, UK) antibodies. Visualization of specific labeling 
with diaminobenzidine as a colored substrate and hematoxylin counterstaining was 
performed with an UltraView Universal Diaminobenzidine Detection Kit (Ventana 
Medical Systems, Inc., Oro Valley, Arizona, USA), which is an indirect, biotin-free 
system for detecting mouse IgG, mouse IgM, and rabbit primary antibodies. The applied 
antibody concentrations and dilutions were 1:1000 for VDR and 1:100 for insulin 
receptor beta. For the negative control, we used the same tissue before applying the 
primary antibody (knockout tissue samples were not available). Insulin receptor beta 
connective tissue samples (fibroblasts expressing the receptor) were used as a positive 
control for VDR colon samples. Microscopic images of the stained vessels were taken 
by the Zeiss Axio Imager system (Zeiss, Oberkochen, Germany). The positively stained 
area was measured as the percentage of total tissue area in the intimal and medial layers 
of the vessel walls using ImageJ software (NIH, Bethesda, Maryland, USA). 
 
3.12 Statistical analysis 
 
For statistical analysis, we used GraphPad Prism 6.0 (GraphPad Software, Inc. 
San Diego, California, United States). A two-way repeated-measures analysis of 
variance (ANOVA) was used for statistical analysis of the curves (e.g., the cumulative 
concentration-diameter curve). Discrete parameters (e.g., bodyweight) were compared 
with one-way ANOVA. The Tukey test was used as a post-hoc test, and p < 0.05 was 
uniformly accepted as the threshold for statistical significance. Data are shown as mean 







4.1 Bodyweight, heart weight, and body mass gain 
ratio 
 
After eight weeks of treatment, regular transdermal T administration resulted in 
higher body weight (p < 0.01). VDD also provoked bodyweight changes. It resulted in 
significantly higher mass gain ratios in transdermal T-free animals (p < 0.05). 
T treatment led to significantly higher heart weights (p˂0.01) compared to VD-
treated and transdermal T naïve rats. Without chronic transdermal T, VDD caused no 
further changes in heart weight values. Similarly, no significant differences in heart 
weight or body weight ratio were observed among the four groups. The results are 
shown in Table 1. 
 
4.2 Serum hormone and leptin levels 
 
A VDD diet produced serum 25-hydroxicholecalciferol levels about fivefold 
lower compared to the supplemented groups (p ˂ 0.01). Oral VD supplementation led to 
normal VD levels and excluded hypovitaminosis D in the treated groups. 
To prove the effectiveness of the transdermal T treatment, serum levels were 
tested on the eighth week of treatment. The levels of elevated serum T (p < 0.01) and its 
active metabolite, 5-DHT (p < 0.05), were detected in transdermally treated animals. 
Serum progesterone levels were reduced, leading to missing or disturbed luteinization. 
Both the above-mentioned features—hyperandrogen status and problems with 
luteinization—are typical in PCOS females. Serum leptin levels were significantly 
elevated as a result of T treatment (but only in the VD-supplemented group; p < 0.05). 





Table 1. Mean final bodyweights, body mass gain ratio, mean heart weight, steroid 
hormone, and leptin serum levels on the eighth week of treatment and the mean 
number of complete estrus cycles during the 14 days of the protocol in the four 
treatment groups. T-treated animals had significantly higher body and heart weights 
compared to double control animals. The treatment protocol resulted in appropriate sex 
hormone and VD serum levels. The highest leptin levels were detected in VD+/ T+ 
animals. Not only T treatment but also VDD had a significantly negative impact on the 
number of estrus cycles, which corresponds to the ovulatory pattern changes seen in 
PCOS cases. Groups of female animals: VD+, VD-supplemented; VD-, VD-deficient; 
T+, transdermal T-treated; T-, transdermal T non-treated. The significances are as 
follows: †, †† significant difference between T-treated and non-T-treated animals (p < 
0.05 and p < 0.01, respectively); * significantly different from VD+/T- (double control) 
animals (p < 0.05); ‡ significantly different from corresponding animals kept on a VDD 
diet (p < 0.01). Results are shown as mean ± SEM. 
 VD+/T- 
n = 12 
VD+/T+ 
n = 12 
VD-/T- 
n = 11 
VD-/T+ 
n = 11 
Final mean 
bodyweight (g) 
282.58 ± 6.25 327.83 ± 8.32†† 296.95 ± 3.94 321.55 ± 3.21†† 
Body mass 
gain ratio (%) 
267.68 ± 6.51 305.98 ± 
10.78††* 




1.15 ± 0.05 1.46 ± 0.06* 1.27 ± 0.03 1.36 ± 0.03* 
Testosterone 
(ng/ml) 




0.10 ± 0.01 0.62 ± 0.14† 0.12 ± 0.02 0.60 ± 0.16† 
Progesterone 
(ng/ml) 




32.33 ± 4.49‡ 33.11 ± 4.46‡ 6.04 ± 0.63 6.01 ± 0.68 
Leptin (ng/ml) 64.55 ± 9.53 153.88 ± 26.16† 118.97 ± 16.23 113.85 ± 28.47 
Mean number of 
estrus cycles 
(days) 






4.1 Ovarian morphology and estrus cycle 
 
After the eighth week of treatment, ovary morphology was examined and the total 
numbers of follicles and corpora lutea were counted. The mean area and total ovary area 
were also calculated in representative samples of each animal group (n = 6). According 
to observation of microscopic ovarian morphology, dominant follicles and corpora lutea 
were detectable only in VD-treated and transdermal T-free rats (Fig. 7).  
 
 
Figure 7. Representative hematoxylin-eosin stained pictures of the ovaries from 
each group. Only VD+/T- animals showed normal follicle development and a normal 
number of corpora lutea. Polycystic morphology was detectable after transdermal T 
treatment, but VDD alone caused similar changes and led to an elevated number of non-






Regarding the mean number of follicles, not only transdermal T treatment but also 
VDD led to a significantly increased number of follicles (p < 0.05 for all groups in 
comparison to the VD-supplemented, transdermal T-free group). Many small-sized 
primordial follicles were present in the samples, which is a typical feature in PCOS. The 
number of follicles and their area ratio were significantly higher in the T-treated groups 
compared to their counterparts (p < 0.05 for both comparisons; Figs. 8A and 8B). The 
corpus luteum was practically missing in T-treated animals, regardless of VD status, 
which issued in a significantly lower number of corpora lutea and mean area surface (T-
treated vs. T-naïve, p ˂ 0.0001, for both the VD-supplemented and VD-deficient group; 
Figs. 8C and 8D). Again, VDD alone reduced the number of corpora lutea and surface 
area (p < 0.05), contributing to polycystic ovary morphology. 
Changes in the normal estrus cycle could be easily judged by daily vaginal smear 
examinations. The normal cycle lasts about 96 hours and consists of four phases. During 
proestrus, it is common for round and nucleated epithelial cells to be present. The estrus 
phase is characterized by non-nucleated, cornified epithelial cells. Metestrus features a 
low number of cells with many shattered cell parts, and diestrus is easy to identify due 
to the large amounts of lymphocytes and mucus. The mean number of estrus cycles 
observed during the last 14 days of the treatment period is shown in Table 1. Non-T-
treated, VD-supplemented females had the highest number of intact estrus cycles. In 
VD-deficient, transdermal T-free animals, a significantly lower number of cycles was 
detected (p < 0.05 compared to counterparts; n = 12 in each group). If transdermal T 
treatment was applied, the normal number of estrus cycles was dramatically reduced (p 
< 0.01 in both comparisons; n = 11 for each group). 
To briefly summarize the above data, PCOS morphology (high amount of small, 
primordial follicles or a missing or low number of corpora lutea) and irregular ovulation 
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Figure 8. Mean numbers and total area ratio of follicles and corpora lutea. The 
bars show (A and C) the mean numbers of follicles and corpora lutea and (B and D) the 
mean percentages of the area ratio of follicle and corpora lutea compared to the total 
ovary area of each group. In PCOS cases, a high number of small primordial follicles 
and a low number of corpora lutea are typical. These typical changes were significantly 
detectable in both T-treated groups. The VD-supplemented, T-free group showed 
normal numbers of follicles and corpora lutea. Significances are shown above the bars. 
Data are shown with SEM in each group (n = 6) at the eighth week of treatment. 
Abbreviations: VD+, VD-supplemented; VD-, VD-deficient; T+, transdermal T-treated; 





4.2 Transthoracic echocardiography and blood 
pressure results 
 
Transthoracic echocardiography was performed at the end of the study protocol to 
detect early changes in wall dimensions and cardiac pump function. The 
echocardiographic assessment revealed no significant difference in the left ventricle end 
diastolic volume or ejection fraction. No significant differences in parameters that were 
sensitive to left ventricular hypertrophic transformation (IVSD and end-diastolic 
volume of the left ventricle) were detected (Table 2). Blood pressure and heart rate 
values did not differ significantly among the four groups. 
 
Table 2. Hemodynamic parameters, left ventricular dimensions, and in vivo pump 
functions of rats assessed by echocardiography at the eighth week of treatment 
(mean ± SEM). No significant changes were observed in the measured parameters 
among the four groups. IVSD(d): thickness of interventricular septum measured in a 
cross-sectional image at the level of the papillary muscles in diastole. All results shown 
as mean ± SEM. 
 
 VD+/T- 
n = 12 
VD+/T+ 
n = 12 
VD-/T- 
n = 11 
VD-/T+ 
n = 11 
IVSD(d) (cm) 0.21 ± 0.01 0.20 ± 0.01 0.20 ± 0.03 0.22 ± 0.01 




0.31 ± 0.01 0.29 ± 0.01 0.32 ± 0.02 0.27 ± 0.02 
Ejection fraction (%) 69.2 ± 2.2 67.5 ± 3.2 66.9 ± 2.2 64.9 ± 2.0 
Fractional shortening (%) 40.5 ± 1.4 40.4 ± 2.6 43.1 ± 1.4 38.9 ± 2.9 
Cardiac output (cm
3
/min) 83.8 ± 5.0 72.8 ± 4.1.6 86.3 ± 4.5 64.0 ± 4.6 
Heart rate (beat/min) 378 ± 4 371 ± 4 401 ± 10 362 ± 9 
Systolic blood pressure 
(mmHg) 
133.2 ± 4.1 149.2 ± 3.6 133.8 ± 7.0 139.3 ± 5.3 
Mean arterial blood pressure 
(mmHg) 
110.5 ± 4.2 120.0 ± 4.2 106.2 ± 5.7 116.6 ± 6.0 
Diastolic blood pressure 
(mmHg) 






4.3 Geometry of the coronary arteriole 
 
Coronary arterioles with similar outer diameters in situ underwent 
micropreparation and were used for further pressure angiography. After reaching a 
passive relaxation state in calcium-free solution after 50 mmHg of pressure, the inner 
and outer diameters of the vessel were measured. The inner and outer radii were 
computed based on the measured inner and outer diameter results as mentioned above. 
VD-deficient groups had significantly higher wall thickness, narrower passive 
lumina and lower inner radii values (p < 0.01 in all comparison to VD-supplemented 
groups; Figs. 9A and 9B). The ratios of the outer radius and wall thickness showed the 
significant result that the VD-/T+ group had the smallest vessels with the thickest walls 
(Fig. 9C; p < 0.05 versus VD-/T-; p < 0.01 in comparison to both VD+ groups). 
The significant effect of VD availability on morphological modeling of the 
coronary arteriole is revealed by alterations in the results of the cross-sectional area (i.e., 
the amount of wall material). While it was the highest in the double control group, VD-









) were observed in the T-free and T-treated VD-deficient groups, respectively. 
Independently of VD supplementation, T treatment reduced the cross-sectional area 
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Figure 9. Geometric properties of intramural coronary resistance arteries from 





thickness as a function of intraluminal pressure in calcium-free solution (full 
relaxation). The wall thickness values of both VD- groups are significantly higher (p < 
0.01 in both comparisons) than those of VD+ groups. B. Inner radius in the fully relaxed 
state as a function of intraluminal pressure. Here again, VDD caused significantly lower 
inner radii values in both groups compared to VD+ groups (p < 0.01 in both 
comparisons). C. Outer radius and wall thickness ratios in calcium-free solution. These 
results suggest that the coronary arterioles of the VD-/T+ group were the smallest 
vessels with the thickest wall. * VD-/T+ differs significantly from VD-/T- group (p < 
0.05); ** VD-deficient group significantly differs from both VD-supplemented groups 
(p < 0.01). N = 11 for each group. Abbreviations: VD+, VD-supplemented; VD-, VD-
deficient; T+ with transdermal T treatment; T-, without T treatment; VDD, vitamin D 
deficiency. The significances of the ANOVA tests are shown. All values are expressed 
as mean ± SEM. 
 
 
4.4 Control of coronary arteriolar smooth muscle tone  
 
Myogenic tone is essential for resistance artery function and autoregulation of 
local blood as well as protection against drastic intraluminal pressure changes. Alone or 
in combination, VDD and T treatment resulted in a significant reduction of myogenic 
tone compared to the double control (Fig. 10A; p < 0.01). 
To examine how much additional substantial contraction could be achieved, a 
potent thromboxane A2 agonist, U46619 (1 µmol/l at 50 mmHg) was used. In our 
“noxa-free” control group (VD-supplemented, transdermal T-free animals), 54.6 ± 3.2% 
contraction was recorded. According to our observations, T treatment did not affect the 
substantial contraction capacity (54.1 ± 4.1%). Developed tone was notably reduced in 
VDD: 26.7 ± 4.7% and 34.8 ± 1.9% of contraction were recorded in the VD-deficient T-
free and T-treated groups, respectively (p < 0.01 in comparisons of VD-supplemented 





After thromboxane A2 agonist contraction, adenosine was used to induce 
endothelial-dependent relaxation of smooth muscle in arterioles. Our findings showed a 
clear connection between VD-supplemented groups, T administration, and endothelial- 
dependent relaxation capacities; the double control segments produced significantly 
better relaxation than the double noxa segments (p < 0.01; Fig. 10B). 
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Figure 10. Contractile and relaxation properties of intramural coronary resistance 





presence of any of the applied noxa, significant myogenic tone reduction compared to 
the noxa-free (VD+/T-) group was calculated. B. Relaxation induced by increasing 
concentrations of adenosine at 50 mmHg pressure. VD deficiency, alone or in 
combination with T treatment, resulted in diminished adenosine-induced relaxation of 
the arterioles compared to the double control group. **, *** VD-deficient group 
significantly differs from the corresponding VD-supplemented group (p < 0.01 or 
0.001). $$ Double control (VD-supplemented, T treatment-free) animals were 
significantly different from animals with double noxa (VD-deficient, T-treated; p < 
0.01). †† T-treated and T-free animals were significantly different (p < 0.01). 
Abbreviations: VD+, VD-supplemented; VD-, VD-deficient; T+, with transdermal T 
treatment; T-, without transdermal T treatment. The significances of ANOVA tests are 
shown. All values are expressed as mean ± SEM. 
 
4.1 Elasticity of the coronary arteriolar wall 
 
Tangential wall stress was measured in normal Krebs solutions (Fig. 11A). 
According to our findings, tangential wall stress was significantly diminished in both 
VD-deficient groups compared to the VD-supplemented groups, regardless of T 
treatment (p < 0.001 in all comparisons). To evaluate further elastic characteristics of 
the vessel wall, the tangential elastic modulus was calculated and plotted against 
tangential wall stress. With the help of these calculations, the elasticity of wall material 
could be judged independently based on geometrical properties. 
Measured values of 25 kPa (high stress) are shown in Fig. 11B. A significantly 
reduced elastic modulus was found in the presence of VDD.  
T treatment led to further value reduction, but this observation was only true in 
VD-deficient female rats (Fig. 11B). If the elastic modulus was plotted against 
intraluminal pressure (Fig. 11C), intraluminal-pressure-dependent differences were 
found. At low pressure ranges, all three treated groups differed significantly from our 
double controls (the VD-supplemented, transdermal T-free group; p < 0.05 in all three 
comparisons). Nonetheless, an increase in intraluminal pressure led to further 
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Figure 11. Tangential wall stress in normal Krebs solution and elastic properties of 





intraluminal pressures above 50 mmHg, both VD- groups differ significantly from both 
VD+ groups (p < 0.001 in all comparisons). B. Incremental elastic moduli (logEinc) at 
tangential stress of 25 kPa. Both VD- groups had reduced incremental elastic moduli 
values compared to both VD+ groups. The significances of ANOVA tests are shown 
with numbers. C. Elastic modulus as a function of intraluminal pressure. At low 
pressure ranges, all three treated groups differed significantly from the double control (p 
< 0.05 in all three comparisons). At higher intraluminal pressure ranges, the VD-/T+ 
group showed further significant reduction than VD+ groups (p < 0.001). *** At 
intraluminal pressures above 50 mmHg, both VD-deficient groups statistically differ (p 
< 0.001 with ANOVA) from the VD-supplemented group. † VD-supplemented, 
transdermal T-free, and the other three groups significantly differ from each other (p < 
0.05). $ Significant difference between VD-supplemented, transdermal T-free, and 
double noxa group (p < 0.05). ### Significant difference between VD-deficient, T-
treated, and both VD-supplemented groups (p < 0.001). Abbreviations: VD+, VD-
supplemented; VD-, VD-deficient; T+, with transdermal T treatment; T-, without 
transdermal T treatment; Tg stress, tangential wall stress of the arteriole; logEinc, 
incremental elastic modulus of the vessel wall, logEinc(logkPa), elastic modulus as a 
function of intraluminal pressure. 
 
 
4.2 Elastica staining 
 
A significant increase in the elastic components of the vessel wall occurred when 
either of the noxa was present. This observation could be quantitatively established by 
measuring the green density along a line that starts from the endothelial surface and is 
driven radially outward. The presence of fewer green components indicates a greater 
amount of elastic density because of its suppression by the magenta color of the elastica 
stain. In the vessel wall of double control animals (VD-supplemented, transdermal T-
free), significantly fewer elastic components were detected (Fig. 12A, p < 0.05). On the 
other hand, both VDD and T treatment had an impact on elastic components, which can 





Figure 12B shows a representative picture of the resorcin-fuchsin stained vessel 
sections of each group. 
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Figure 12. Density of elastic fiber and representative pictures of resorcin-fuchsin 
stained histological sections of intramural coronary resistance arteries from VD-






elastic fibers analyzed in RGB pictures of resorcin-fuchsin stained vessel sections. As 
magenta suppresses green, a low level of green color intensity is typical if elastic fibers 
are present. B. Representative picture of resorcin-fuchsin stained vessel sections of each 
group. Abbreviations: VD+, VD-supplemented; VD-, VD-deficient; T+, with 
transdermal T treatment; T-, without transdermal T treatment. The significances of 
ANOVA tests are shown. All values are expressed as mean ± SEM. * VD-
supplemented, non-T-treated animals differ from all other groups (p < 0.05). 
 
 
4.3 OGTT: plasma glucose, insulin and HOMA IR 
levels 
 
Oral glucose tolerance levels are shown in Figure 13A. No significant difference 
in fasting glucose levels among the four groups could be detected. Considering the 60-
minute post-load blood sugar levels, VD-supplemented, transdermal T-treated rats 
developed significantly higher blood sugar levels compared to the double control (p < 
0.05). Nevertheless, T treatment altered 120-minute post-load values, which were 
significantly higher for the T-treated animals than for both groups of T-free animals (p 
< 0.05 and p < 0.01, respectively). Although the VD-deficient and transdermal T-treated 
group showed a slight elevation in 60-minute results, no significant difference could be 
detected during the OGTT protocol.  
Regarding basal plasma insulin levels measured before OGTT, we observed no 
significant changes among the four groups. However, the 120-minute values of the VD-
deficient, T-untreated group were significantly higher than those of their VD-
supplemented double control counterparts (Fig. 13B, p ˂ 0.05). Moreover, the computed 
HOMA IR results of both VD-deficient groups were significantly higher (Fig 13C, p < 
0.05) than those of the VD-substituted double control animals. Mild elevation of 
HOMA IR was detected in the VD-supplemented, T-treated group, but this alteration 
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Figure 13. Results of OGTT: plasma glucose, insulin, and HOMA IR. A. Plasma 





for each group). B. Plasma insulin levels following OGTT (n = 6). C. Calculated 
HOMA IR values (n = 11 for each group). Both T+ groups had significantly elevated 
120-minute blood sugar levels compared to the T- groups (p < 0.05), but these results 
were not accompanied by significant plasma insulin concentration changes. The VD-/T- 
group had a significantly higher 120-minute plasma insulin concentration compared to 
the VD+/T- group. HOMA IR results revealed that both VD- groups had IR. 
Abbreviations: VD+, VD-supplemented; VD-, VD-deficient; T+, T-treated; T-, without 
T treatment. Significances of ANOVA tests are shown. * Significant difference between 
the VD-supplemented, T-treated and T-free (double control) animals (p < 0.05). #, †† 
Significant difference between T-treated and both non-treated animal groups (p < 0.05 
and p < 0.01, respectively). $ VD-deficient, transdermal T-free animals significantly 
differ from corresponding animals kept on a VD diet (p < 0.05). 
 
 
4.4 Insulin-induced relaxation in coronary arterioles 
An increased concentration of insulin was added to the organ chamber to 
investigate its effects on coronary arteries (Fig. 14A). One of the two noxa was enough 
to significantly reduce insulin-induced relaxation (p < 0.01 in all three groups compared 
to the double control animals). At higher insulin concentrations, no relaxation could be 
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Fig 14. Insulin sensitivity and receptor expression in the walls of coronary 
arterioles. A. In vitro relaxation of intramural coronary arterioles in response to 
elevated concentrations of insulin. B and C. Immunohistochemical density of insulin 





density of VDR in the endothelium and media, respectively. B–E. Total area ratio 
percentages (n = 6 in all groups). Insulin-induced relaxation capacities were 
significantly reduced in VDD and hyperandrogenism if an elevated concentration of 
insulin was added to the organ chamber. The insulin receptor beta and VDR density 
across the vessel wall was significantly elevated in both VD- groups (significance 
values are shown above the bars). Abbreviations: VD+: VD-supplemented; VD-: VD-
deficient; T+: treatment with T; T-: no T treatment. A–E. Means ± SEM. Significances 
of ANOVA tests are shown. *, ** All the other groups were significantly different from 
the VD-supplemented and T-treatment-free (VD+/T-, double control) group (p < 0.01 




4.5 Insulin and vitamin D receptor density in coronary 
arteriolar tissue 
 
To reveal insulin receptor and VDR density through the coronary arteriole wall, 
we used immunohistochemistry. According to our findings, VDD affects the expression 
of the insulin receptor in the endothelial and media layers. In both groups, regardless of 
T treatment, we measured significantly higher insulin receptor density (Figs. 14B and 
14C; p < 0.001 in all VD-supplemented comparisons). Additionally, greater VDR 
density was found in VDD female animals (Figs. 14D and 14E; p < 0.01 and 0.001). 
This difference was more pronounced in the media layer, and T treatment resulted in no 
further differences between the two groups. Figures 15A and 15B show representative 







Fig 15. Representative pictures of insulin (A) and VD (B) receptor density in 
vessel sections. Abbreviations: VD+, VD-supplemented; VD-, VD-deficient; T+, 










5.1  Phenotypical and cardiometabolic changes after 
transdermal testosterone treatment with and without vitamin 
D deficiency 
 
According to some estimations, VDD affects 67–85% of the hyperandrogenic 
female population worldwide [115]. It serves as an aggravating risk factor for 
cardiovascular and metabolic diseases, such as stroke, acute coronary syndrome, or 
diabetes mellitus [6, 145, 155-158]. Additionally, AE and low VD serum levels could 
trigger the occurrence of IR and coronary disease. Our aim was to reveal the possible 
interplay of these factors and the effect of this interplay on coronary microvascular 
damage in PCOS with or without VDD. 
In our model, transdermal T was applied to provoke AE. T gel was introduced in 
the early 2000s as a treatment for the hypogonadic state in males [159]. As this 
application results in good bioavailability, quickly achieves steady-state plasma levels 
(within the first 48 hours after administration), and is easy to use, it is an ideal agent to 
investigate androgen state alterations in rodents [160]. As far as we know, this was the 
first time that hyperandrogen PCOS was induced by chronic transdermal T gel 
administration.  
According to the latest recommendations of the Androgen Excess and PCOS (AE-
PCOS) Society [161, 162], clinical or biochemical hyperandrogenism is crucial to 
diagnose PCOS in humans, and the oligo-anovulatory PCO form of ovulatory 
dysfunction is required. At the end of our study protocol, markedly elevated levels of 
serum T and its active metabolite, DHT, were measured in treated animals (Table 1). In 
contrast, untreated animals maintained normal sex steroid levels, proving the efficiency 
of our transdermal T regime. Hyperandrogen female rats developed phenotypic changes 
in PCOS, including higher body weight and body mass gain ratio, similar to the changes 





The goal VD status was achieved in specific groups. Oral VD supplementation 
ensured high normal levels, while VD-deficient nutrition resulted in VDD (Table 1). 
We concluded that our study successfully reproduced a range of VD serum levels in 
rodents similar to those observed in various human studies investigating the level of 
VDD in the adult PCOS female population [158, 163]. 
In addition to hyperandrogenism, the gonadal features of PCOS include chronic 
ovulation irregularities and ultrasound diagnosis of polycystic ovary morphology. 
Transdermal T-treated female rats failed to develop regular estrus cycles, which led to 
both a low follicle rate and a remarkable reduction in the number of corpora lutea. We 
detected that VD-deficient animals without hyperandrogenism had irregular estrus cycle 
patterns, an elevated number of follicles, and a reduced number of corpora lutea. These 
findings could be explained by the multiple regulatory roles of VD in ovarian follicular 
development and luteinization. As VD affects the signal transduction of AMH, FSH 
sensitivity, and progesterone production of granulosa cells, PCOS-like ovarian 
morphology and ovulation disturbances are often observed in VDD cases [164]. The 
linkage between AMH levels and VD could explain follicular arrest in VDD cases. 
Whilst AMH inhibits primordial follicular recruitment and decreases the FSH 
sensitivity of growing follicles, the two- to threefold higher AMH serum levels in PCOS 
females could play an essential role in ovulatory dysfunction [165]. AMH also 
negatively controls aromatase activity in granulosa cells and reduces estradiol 
transformation, resulting in higher androgen serum levels. In vitro, the AMH gene is 
regulated by VD through functional VD response elements that bind the VDR [166]. 
Since both hormones show the same seasonal variability and an inverse correlation 
between VD and AMH was proven to exist in fertile females (with low circulating VD 
and high AMH levels), this could be a key element for understanding the effect of VD 
action on ovulatory function [167]. 
Regarding metabolic consequences, our findings revealed that both hormonal 
disturbances could provoke IR. Recently, some human studies pointed out that 
approximately 80% of the PCOS population suffers from IR, but this appears to be 
multifactorial [168]. The correlation between the prevalence of IR and VDD has already 
been investigated [163, 169, 170]. Although there was no difference between fasting 





(after 60 min and 120 min), which was not followed by greater insulin secretion (Figs. 
13A and 13B). In VDD cases, higher insulin output was recorded, but glucose levels 
remained unchanged (Fig. 13B). Interestingly, there was no additional effect between 
VDD and the hyperandrogenic state (i.e., the presence of both noxa did not result in 
worse IR values). These observations suggest that two different paths toward IR could 
be present at one time. In the case of T treatment, serum insulin levels were unable to 
prevent the development of hyperglycemia. This could be due to decreased beta-cell 
sensitivity, which may lead to worsening of hyperglycemia. If VDD is present, higher 
insulin levels could be able to normalize blood glucose levels. In addition, the measured 
HOMA IR values revealed that VDD was enough on its own to provoke IR. If the 
serum levels of VD were optimal, the HOMA IR results of T treated animals were 
unaltered in comparison to transdermal T-free ones (Fig. 13C). When the two noxa were 
combined, a marked elevation in plasma glucose levels were recorded despite higher 
120 min insulin levels. In the double noxa group, HOMA IR and elevated plasma 
glucose levels indicated disturbed insulin homeostasis. 
Leptin, which is an anorexigenic hormone, has multiple roles in the development 
of obesity, metabolic syndrome, and IR. Leptin receptors are present in various tissues, 
including hypothalamus, liver, stomach, adipose, and ovary tissue. In PCOS patients, 
hyperleptinemia combined with IR is frequently present, among other hormone 
disturbances [171]. In our study, we observed that both T treatment (regardless of VD 
status) and VDD led to higher serum leptin levels (Table 1). On one hand, this could be 
interpreted as a consequence of VDR upregulation in adipose tissue [172]. On the other 
hand, leptin is involved in ovarian steroid genesis, suggesting a strong relation between 
higher circulating T levels and hyperleptinemia. In PCOS cases, just like in T2D cases, 
dysfunctional adipocytes are involved in higher activation of anti-apoptotic pathways, 
resulting in higher body mass index and obesity [173]. The higher amount of 
malfunctioning fatty tissue could be responsible for higher leptin levels, which could be 
accompanied by leptin resistance [174]. Recently, some studies pointed out that 
considering the leptin/adiponectin ratio allows for better evaluation of the long-term 
metabolic complications in both the lean and obese PCOS populations. According to 
these data, altered hormone secretion in adipose tissue could be more important for 





According to recent guidelines, screening for cardiovascular risk factors should be 
implemented early in young fertile females with PCOS [162]. In PCOS women with or 
without actual cardiovascular risk factors, regular check-ups that include measurements 
of blood pressure and lipid profile control are recommended on a yearly basis.  
At the end of our study, we observed slight elevation of the systolic, diastolic, and 
mean arterial blood pressure values in both T-treated groups. In humans, these results 
might be regarded as early alterations and regular follow-ups would be necessary 
according to recent guidelines. Although the cardiac output results were mildly reduced 
in both T-treated groups, all of the other echocardiographic parameters remained 
unchanged (compared to our double controls). Although hypertension and changes in 
cardiac pump function are considered to be late-onset cardiovascular complications, 
their predicting factors have been reported to be present in the early stage of human 
PCOS. Humoral factors, such as high normal aldosterone serum levels (excluding 
primary hyperaldosteronism), could be one of the first steps toward dysregulation of the 
renin–angiotensin aldosterone axis [176]. Evaluation of atherogenesis based on carotid 
intima-media thickness or the circulating levels of insulin, total cholesterol, LDL-C, C 
reactive protein, and serum interleukin-18 could be also useful for predicting subclinical 
cardiovascular disease [98]. 
 
5.2 Biomechanical and pharmacological changes of the 
coronary arterioles 
 
We observed that not only hyperandrogen status (transdermal T treatment) but 
also chronic VD withdrawal alone resulted in fundamental changes in arteriolar 
geometry. Smaller inner radii and greater wall thickness was observed in both VD-
deficient groups. Interestingly, if both conditions were present (VDD and AE), no 
further aggravation (greatest wall thickness and smaller lumina) could have been 
detected (Figs. 9A and 9B). These findings suggest that accompanying VDD would 





The antiatherosclerotic role of VDR signaling in leukocytes/macrophages was 
described recently. VD is involved in antiatherosclerotic mechanisms, which inhibit the 
activation of the local renin-angiotensin system in macrophages and in the 
atherosclerotic lesion itself [177]. On the other hand, VDD leads to remodeling 
triggered by the migration of leukocytes into the vessel wall, early vessel wall 
calcification, and activation of endothelial cells and pericytes [178]. In PCOS patients, 
androgen-induced hypertension is the first step toward long-term changes in vessel 
biomechanics [179]. As reported previously, this complex phenomenon causes inward 
hypertrophic remodeling in peripheral resistance vessels, in which the media thickens to 
the disadvantage of the lumen, resulting in an increased cross-sectional area and media-
to-lumen ratio [147]. Moreover, higher intima media thickness values have been 
reported in human muscular arteries among PCOS patients [180, 181]. In our study, 
coronary arteriole geometry did not correlate with blood pressure, as could have been 
expected based on Folkow’s law [182]. Nevertheless, VD had indisputably trophic 
effects on the coronary arteriolar wall, as VDD is accompanied by increased wall 
thickness and luminal reduction. On the other hand, T-induced alterations were not 
detected as expected, and arteriole wall mass was decreased in hyperandrogen female 
rats. In light of these findings, we assume that T might have some kind of inhibitory 
effect on female coronary arteriolar wall trophism. This observation is supported by 
some recent data regarding the hormone-dependent activation of specific matrix 
metalloproteinase subfamilies. These enzymes play a key role in vascular smooth 
muscle cell migration and remodeling. It was shown that male (T and DHT) and female 
(estrogen and progesterone) sexual steroids maintain a balance between matrix 
metalloproteinases in vascular smooth muscle cells [183] in a gender-dependent 
manner. 
Myogenic tone is essential for arteries to maintain optimal blood flow during 
hypo- and hypertension. In coronary arterioles, this ability is crucial to optimize 
ventricular blood flow and maintain constant perfusion for myocardium. According to 
our findings, both VDD and hyperandrogen states resulted in a reduction in the 
substantial spontaneous myogenic tone of the examined coronary segments (Fig. 10A). 
This observation supports the above-mentioned theory regarding altered vascular 
smooth muscle cell migration, as spontaneous myogenic tone involves a contraction 





could be damaged by different mechanisms, as VD has direct regulatory effects on 
vascular smooth muscle growth and calcification. Under normal circumstances, VD 
inhibits the proliferation of vascular smooth muscle cell by acute influx of calcium into 
the cell and increases cellular calcification. In addition, cardiomyocytes express VDRs, 
which enables the conversion of calcidiol to calcitriol. In this regard, VDD could be 
plausible for alterations in vascular smooth muscle cell trophism [120]. 
Thromboxane A2 agonist-induced maximum contraction and adenosine-induced 
vasodilation were decreased in the presence of VDD (Fig. 10B). On one hand, VD 
supplementation in AE was able to compensate for both the maximal contraction and 
relaxation capacities. On the other hand, VDD attenuated the adaption capacity of 
coronary arterioles, although T was mainly responsible for changes in relaxation 
capacity. We conclude that both noxa deteriorate the vessel’s capability to adjust local 
ventricular flow to meet higher metabolic demand. If such vascular tone disturbances 
persist in small coronary arterioles, alterations in myocardium trophism and higher CV 
risk could be long-term consequences.  
Tangential stress is the stress surrounding the circumference of a pipe due to a 
pressure gradient. As blood flow is normally laminar through most of the circulatory 
system, tangential wall stress is important for judging the stress profile of arteriolar 
walls. In vivo, low tangential stress or changing shear stress direction can be found in 
conditions of turbulent flow, which is typical in bifurcations or the presence of 
atherosclerosis. These mechanisms could promote endothelial shape changes, 
proliferation, and apoptosis. Turbulent flow also triggers the secretion of 
vasoconstrictive agents, coagulation, and platelet aggregation. Advanced atherosclerotic 
lesions with arterial stiffening and reduced flow-mediated dilatation have already been 
described among patients with VDD and chronic renal failure [184]. Our results could 
suggest a possible imbalance in laminar and turbulent flow, as tangential stress values 
were significantly reduced in both VD-deficient groups (Fig. 11A).  
The elastic properties of the coronary arterioles are useful indicators to evaluate 
possible vascular remodeling. In both VD-deficient groups, the elastic modulus 
parameters were reduced under the same tangential wall stress (high wall shear stress 
value: 25 kPa, Fig. 11B). The lowest values were observed when VDD and a 
hyperandrogen state were present at the same time (p < 0.01 and 0.05, respectively). We 





pressure range, T treatment resulted in a significant elevation in our values (p < 0.05), 
but in the high blood pressure range, VD caused a significant reduction (p < 0.001). To 
determine which wall component is responsible for the above-mentioned changes, we 
measured elastic density in the vessel wall (Figs. 12A and 12B). Our elastica staining 
results correlated well with the changes in vessel biomechanics, and corresponding 
significant alterations were found under the above-mentioned circumstances. Based on 
our results, we could conclude that VDD and AE could be responsible for the early 
steps of remodeling, as the elastic components of the vessel wall were altered by both 
noxa. 
 
5.3 Insulin resistance of the coronary arterioles 
 
The effects of insulin can be divided into two groups: metabolic effects, which are 
supposed to maintain glucose homeostasis, and non-metabolic effects, including 
regulation of mitogenesis and cell growth. In the vasculature, insulin is responsible for 
eNOS-mediated vasodilation. In the short term, this vasodilatation aids glucose 
distribution and promotes capillary recruitment. As a general consequence, it also 
improves blood flow, which protects against vascular aging and atherosclerosis. It is 
clear that some kind of dysregulation of insulin-dependent vasodilation could serve as 
an independent risk factor for cardiovascular events. 
The action of insulin is mediated by two different receptors: the “classic” insulin 
receptor and the related IGF-1 receptor [185]. As both receptors are ligand-activated 
tyrosine kinases, they could initiate several phosphorylation cascades. The main 
characteristics of the two insulin receptors are different in some ways. On one hand, 
they are both expressed on cell surfaces, including endothelial cells. On the other hand, 
their insulin-mediated activation is concentration-specific. It was recently reported in 
human cells that insulin in physiological concentrations (<10 nM) selectively enhances 
autophosphorylation of the classic receptor. If the supraphysiological insulin 
concentration (>10 nM) is applied, autophosphorylation of the IGF-1 dominated over 
the classic receptor [92]. As hyperinsulinemia is typical in IR, the above-mentioned 





vasodilatation and eNOS activation. A recent investigation aimed to identify in bovine 
and porcine aortic endothelial cells which receptor pathway is a determinant of eNOS 
activation. Interestingly, the classic insulin receptor seems to play a key role, as high 
insulin dose and IGF-1 receptor inhibitors had no or little impact on eNOS activation 
[186, 187]. Based on these findings, we speculated that any type of dysfunction in the 
“classic” insulin receptor-mediated cascade might result in disturbances in insulin-
mediated vasodilatation. 
It has already been noted that the metabolic features of IR were present in both the 
hyperandrogen and VD-deficient groups due to our treatment. Our results indicated the 
possibility of two different, but not additive, IR mechanisms: after OGTT in VD cases, 
hyperinsulinemia was detected with normal blood sugar levels, and in a hyperandrogen 
state, high blood sugar levels were combined with slightly elevated serum insulin levels. 
We tested insulin-induced relaxation with an elevated concentration of insulin, as our 
aim was to investigate the effect of hyperinsulinemia on the typical state of IR. Some 
reduction in relaxation was detected after administration of a physiologic concentration 
of insulin (which would be normal under intact in vivo circumstances). After applying 
the supraphysiological insulin concentration (similar to hyperinsulinemia), more 
expressed reduction was observed, which turned into vasocontraction (negative 
dilatation values) at peak concentrations (Fig. 14A).  
According to our immunohistology results, we suggest the following possible 
explanations for the observed phenomena. In hyperandrogen females with normal serum 
VD levels, T alone attenuated insulin-induced relaxation (Fig. 14A) but had no impact 
on the number of insulin receptors in the vessel wall (Figs. 14B and 14C), as the double 
control group had similar values. It is important to add that the HOMA IR index (Fig. 
13C) was also elevated in this group, but the values could not reach significance. 
Therefore, the key element of IR is probably not a changed number of receptors, but 
specific signaling pathways of vascular insulin receptors.  
One possible reason for such disturbances could be the downregulation of PI3-K-
dependent insulin signaling. Normally, in the vasculature, activation of insulin receptors 
could maintain a balance between the PI3-K-dependent pathways, which regulate 
endothelial NO production, and the MAPK-dependent insulin signaling pathways, 
which trigger secretion of the vasoconstrictor ET-1. Another important effect of PI3-K 





pathways are suppressed, other pathways would dominate the microvascular response to 
insulin, affecting vasoconstriction (as was observed in our study) and causing 
hyperglycemia [188]. It was already revealed that, in vivo, elevated ET-1 activity is 
typical in coronary vessels with vulnerable or obstructive atherosclerosis. Interestingly, 
in porcine coronary artery rings from both genders, thromboxane A2- and ET-1-
mediated vasoconstriction was elevated by low doses of T. In parallel, endothelium-
dependent relaxation of the coronary rings was diminished in not only males but also 
females. Transcription (actinomycin D) and translation (cycloheximide) blocking agents 
as well as anti-androgens (flutamide and cyproterone acetate) were unable to completely 
antagonize these effects, supporting the modulatory action theory of T [189].  
Selective vascular IR could be a plausible reason for reduced relaxation 
capacities. Vascular endothelium insulin receptor knock-out mice possess normal 
glucose metabolism and blood pressure under normal circumstances, but if a 
cardiovascular risk factor arises, the characteristics of selective vascular IR will appear. 
The hypothesis was verified by a high salt diet challenge, after which knockout mice 
developed hypertension, endothelial dysfunction, and vascular IR [190]. This finding 
suggests that in IR cases, loss of eNOS activation is probably more important than ET-
1-triggered vasoconstriction, as both mechanisms are disturbed in vascular endothelium 
insulin receptor knockout mice. Recent studies showed that not only NO production but 
also its bioavailability are diminished in IR cases, mainly due to the increased 
generation of reactive oxygen species and local activation of the renin–angiotensin 
system [191, 192]. Expression of eNOS mRNA and protein expression in transgenic 
mice with endothelium-targeted overexpression of a dominant-negative mutant human 
insulin receptor did not differ from the wild type. Furthermore, in this study, these 
transgenic animals were normotensive and normoglycemic, but insulin failed to produce 
relaxation on the thoracic aorta rings. Simultaneous overexpression of nicotinamide 
adenine dinucleotide phosphate oxidase isoform (Nox2 and Nox4) mRNA occurred, 
which could blunt the bioavailability of NO to the target cells [193]. According to 
recent data, T has modulatory effects on reactive oxygen species as well. In 
spontaneously hypertensive, ovariectomized female rats, chronic T supplementation 
increased the generation of reactive oxygen species throughout the activation of 
cytosolic nicotinamide adenine dinucleotide phosphate oxidase subunit p47
phox
 and 





endothelial function [194]. In this regard, chronic elevation of circulating T levels could 
be a plausible explanation for different insulin signaling disturbances. 
In addition, VDD alone provoked altered insulin relaxation (Fig. 14A) and 
increased the number of vascular insulin receptors (Figs. 14B and 14C). It seems that 
reduced insulin receptor sensitivity could be responsible for higher HOMA IR values 
(Fig. 13C) and only higher insulin levels can keep postprandial glucose levels within a 
normal range (Fig. 13A). As an end effect, the typical characteristics of IR 
(hyperinsulinemia combined with receptor upregulation and functional alterations) were 
present in VDD cases. Within the double noxa group, the most pronounced damage was 
detected for insulin-induced relaxation, which was combined with the highest insulin 
receptor density. In this group, all features of metabolic syndrome, including increased 
body weight (Table 1), high postprandial glucose levels (Fig. 13A), and pronounced IR 
(elevated HOMA IR; Fig. 13C), were simultaneously present.  
VD has several modulatory function in vivo, but VD supplementation has no 
further positive effect if serum levels are already within the normal range. On the other 
hand, it is well reported that VDD could lead to IR by triggering chronic inflammation. 
VDD promotes the upregulation of pro-inflammatory cytokines like tumor necrosis 
factor α, nuclear factor κB, and specific interleukins, which could trigger c-JUN N-
terminal kinase and the inhibitor of κB kinase. These kinases can target insulin receptor 
substrates 1 for serine phosphorylation, which inhibits insulin receptor signaling and 
leads to IR [195]. 
In our study, VDRs were present in the vessel walls and showed similar density 
patterns to insulin receptors (Figs. 14D and 14E). Recent data suggests that VD could 
modulate insulin sensitivity, and a functional VDR element has been identified in the 
promoter region of the insulin receptor. This promoter region of the insulin receptor 
gene contains one VD response element that is activated by the VDR and RXR 
heterocomplex [196]. In this manner, VD levels could directly regulate insulin receptor 








We studied the metabolic and vascular effects of hyperandrogen PCOS with and 
without VD deficiency in a rat model of PCOS. We also investigated the 
cardiometabolic effects of VD deficiency without additional AE.  
I would like to briefly summarize our results below: 
 A new hyperandrogen-deficient and VDD PCOS rat model was successfully 
created 
The applied transdermal T treatment successfully produced the phenotypical 
changes required for diagnosis of the classic PCOS phenotype. Although VD 
supplementation in rats with AE partially restored ovulatory patterns, polycystic 
ovary morphology was still present. Meanwhile, disturbed ovarian morphology as 
well as estrus cycle irregularities and a reduced amount of corpus luteum could be 
detected among both VD-deficient groups. Although VDD alone did not affect the 
measured sexual steroid serum levels, changes in ovarian morphology were still 
present, as in the oligo-anovulatory polycystic PCOS phenotype without AE. 
Moreover, VDD combined with AE produced the lowest estrus cycle rates, 
highlighting the importance of VD supplementation in hyperandrogen PCOS 
women with a history of problems with conception. 
 
 Major metabolic changes in VDD and AE could be observed at the same time 
Our study revealed that both factors (in combination or alone) were able to induce 
the major symptoms of metabolic syndrome as well as IR. We concluded that AE 
had a very important role in body weight changes, as supported by the fact that 
75% of obese PCOS patient suffer from AE. Neither VD supplementation nor 
VDD had any relevant impact on body weight gain ratio in our study. In line with 
some findings showing that body mass index has an inverse correlation with 
circulating VD levels, it is tempting to speculate that VD insufficiency might be 
responsible for the development of dysfunctional adipose tissue and obesity. 





VD uptake and reduced release across abdominal subcutaneous adipose tissue that 
might be responsible for lower levels of circulating VD. 
 
 VDD and T treatment induced morphological and elastic remodeling of the 
vessel wall 
Narrower passive inner lumina and greater wall thickness were detected in cases 
of VD deficiency, and the presence of T treatment worsened wall properties. 
Although we speculated that T treatment would provoke wall hypertrophism, our 
findings confirmed the opposite for coronary arterioles. One possible explanation 
for the AE-induced hypotrophic remodeling is the activation of different matrix 
metalloprotease subtypes and vascular smooth muscle cell migration rate. In 
addition, the contractile–relaxation range of the arterioles was reduced by VDD 
and AE. Damaged vascular adaptation range has a negative impact on ventricular 
tissue blood flow if a sudden adjustment is needed to alter metabolic needs. 
Reduced spontaneous tone and increased wall rigidity were characteristics of VD-
deficient and T-treated vessels. The presence of both noxa led to the most 
disadvantageous changes in maximal relaxation capacity. Alteration of the 
vessel’s elastic components was observed in cases of both VDD and AE, which 
supports the existence of early wall remodeling.  
 
 VDD and AE provoked IR with different mechanisms 
In cases of T treatment and VD supplementation, AE elevated postprandial sugar 
but generated neither hyperinsulinemia nor HOMA IR elevation. Insulin-induced 
relaxation of the coronary arterioles was also diminished, despite the fact that 
insulin receptor expression was unaltered. VDD, regardless of T treatment, 
resulted in higher postprandial insulin concentrations, elevated HOMA IR values, 
and reduced the insulin-induced vascular response. Moreover, in cases of VD, an 
elevated number of vascular insulin receptors was detected in both the endothelial 
and media layers of the vessel wall. This type of alteration in the number of 
receptors was also measurable in VDR, but the detected changes were much more 
significant at the media layer. Therefore, we conclude that there might be two 
different ways to develop IR, and when combined, they significantly worsen the 





Our results confirmed that both AE and VD could provoke undesirable vascular 
and metabolic alterations to coronary resistance arteries. However, we must admit that 
this study aimed to demonstrate early changes, and hence possible long-term 
interactions should be considered in further research. Our findings support previous 
reports suggesting the importance of treating both AE and hypovitaminosis D in PCOS 








Polycystic ovary syndrome (PCOS) affects 8–12% of fertile reproductive-aged women. 
Vitamin D deficiency (VDD) is a common comorbidity in hyperandrogen PCOS 
females (67–85%). Our aim was to study early biomechanical and metabolic alterations 
to the coronary resistance arterioles in hyperandrogen PCOS and VDD cases. Forty-six, 
4-week-old female Wistar rats weighing 90–110 g were grouped into four groups. 
Twenty-four were kept on a VD-supplemented diet, and 12 of these animals received 
transdermal testosterone (T). Twenty-two animals went on a VDD diet, 11 of which 
were treated with T. Oral cholecalciferol was administered from the second week on. 
Sexual steroid and VD hormone levels were measured at the sixth and eighth weeks. On 
the sixth week, the OGTT was performed and plasma insulin and glucose levels were 
measured. From the sixth week on, a vaginal smear was collected and the estrus cycle 
was examined daily. At the end of the protocol, pressure arteriography was performed 
with coronary segments (diameters of 200 m) taken from the left anterior descendent 
coronary artery. The inner and outer radii were measured with video microscopy. 
Normal myogenic tone, insulin-induced vascular reactivity, and maximal passive 
relaxation and constriction were calculated and statistically analyzed. Insulin receptor 
and VD receptor (VDR) expression were tested based on immunohistochemistry. 
Transdermal T treatment, VDD, and a supplemented diet resulted in appropriate 
hormonal changes. Rats with AE showed significant phenotypical changes in PCOS. 
VDD and AE had a significant impact on the wall thickness, inner lumina, maximal 
passive relaxant potential, thromboxane-induced contraction capacity, and myogenic 
tone. T treatment resulted in impaired glucose tolerance and significantly reduced 
insulin-induced coronary relaxation without hyperinsulinemia and reduction in the 
number of insulin receptors. VDD led to high postprandial insulin levels, altered 
HOMA IR, diminished insulin-induced relaxation, and increased the number of VDR 
and insulin receptors. Combination of VDD and AE resulted in the most 
disadvantageous vascular alterations. Insulin resistance is present both in VDD and AE, 
although their pathomechanisms are different. Therefore, treating AE and VDD at the 







A policisztás ovárium szindróma (PCOS) a fogamzó képes korú nők 8-12% - át érinti; 
az androgén túlsúlyos betegek 67-85 %-a pedig D-vitaminhiányos is. Célunk a 
koszorúserek rezisztencia arterioláinak korai biomechanikai és adaptációs változásainak 
tanulmányozása volt a fenti állapotokban. Negyvenhat, 4 hetes, 90-110 gramm súlyú 
nőstény Wistar patkányt 4 csoportra osztottunk. Huszonnégy D-vitamin pótolt, míg 22 
D-vitaminhiányos étrendben részesült. Mindkét csoport fele heti ötször transzdermális 
tesztoszteron (T) kezelést kapott. A 2. héttől a fenti étrendet orális D-vitaminpótlással 
egészítettük ki. A 6. héten OGTT vizsgálat, plazma inzulin és glükóz mérés történt. A 6. 
és 8. kezelési heten a szexuál szteroid és a D-vitamin szérum koncentrációkat 
megmértük. A 6. héttől napi hüvelyváladék vizsgálatot és ösztrusz cikluselemzést 
végeztünk. A 8. héten in vitro nyomás angiográfiás méréséket végeztünk a bal 
koszorúsér elülső leszálló ágának vég- és oldalágainak 200 mikrométeres külső 
átmérőjű szegmenseivel. Az erek belső és külső átmérőjét videomikroszkópos 
technikával mértük. Az eredményekből spontán miogén tónust, maximális passzív 
relaxációt és konstrikciót, valamint inzulin indukált ér reaktivitást számítottunk. Az erek 
inzulin és D-vitamin receptor sűrűségét immunhisztokémiai vizsgálattal határoztuk 
meg. A kapott eredményeket statisztikailag elemeztük. A transzdermális T kezelés és a 
D-vitaminmentes illetve pótolt táplálás a várt hormonális változásokat okozta. A D-
vitaminhiány és az androgén túlsúly egyaránt negatívan hatott az erek falvastagságára, 
csökkentette belső keresztmetszetük, maximális passzív relaxációjuk, kontrakciójuk és 
spontán tónusuk. A T kezelés az OGTT alatt magas vércukor és normál plazma inzulin 
szintet okozott, melyet az erek csökkent inzulin relaxációja és változatlan inzulin 
receptor sűrűsége kísért. D-vitaminhiányban a normál vércukorszinthez magas 
posztprandiális inzulin értékek társultak, melyhez megnövekedett inzulin és D vitamin 
receptor sűrűsége és károsodott inzulin relaxáció párosult. A D-vitaminhiány és az 
androgén túlsúly együttes fennállása a koszorúsér arteriolák biomechanikai adaptációs 
képességeit károsítja és az érfal remodelingjét okozza. Mind a D-vitaminhiány, mind az 
androgén túlsúly inzulin rezisztenciát okoz, azonban feltehetőleg más mechanizmussal. 
A D-vitaminhiány és az androgén túlsúly egyidejű kezelése kedvezően hat a 
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